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Pluripotent stem (PS) cells retain the ability to differentiate into cells representing the three 
germ layers, mesoderm, ectoderm and endoderm. Embryonic stem (ES) cells isolated from 
blastocysts and reprogrammed somatic cells, described as induced pluripotent stem (iPS) 
cells, are a promising source of PS cells for regenerative medicine. PS cells hold the potential 
to cure cell-specific diseases through autologous transplantation of cells or tissues by prior 
differentiation into specific cell types. If PS cells are transplanted into an immunocompatible 
host they form multidifferentiated tumors, described as teratomas. The control over the 
differentiation process of PS cells still remains a challenge. Reducing or eliminating the 
intrinsic tumorigenicity of PS cells may lead to safer stem cell therapies for treatments of yet 
incurable diseases. A recently developed technology induces early germ cell features in male 
ES cells, defined as gonogenic stimulated transition (GoST) induction. The resulting cells are 
described as GoST cells. In this work we investigated if GoST induction is possible in male 
murine iPS (miPS) cells and tested the tumorigenicity of miPS-derived GoST cells in the 
NSG mouse model. Although GoST cells still contributed to teratoma formation, our results 
showed reduced tumor growth of GoST cells compared to wild type (WT) miPS cells. By 
extending an unstimulated time period after GoST induction, expression of spermatogonial 
stem cell markers was observed. 
Zusammenfassung 
Pluripotente Stammzellen (PS Zellen) sind fähig sich in Zellen zu differenzieren, die die drei 
Schichten des Urkeims repräsentieren. Embryonale Stammzellen (ES Zellen) aus 
Blastozysten und reprogramierten somatischen Zellen, sogenannte induzierte pluripotente 
Stammzellen (iPS Zellen), sind eine vielversprechende Quelle von PS Zellen für die 
regenerative Medizin. PS Zellen haben das Potential, zellspezifische Krankheiten durch 
autogenen Ersatz von Zellen oder Geweben durch Differenzierung in den jeweiligen Zelltyp 
zu ermöglichen. Autogen transplantierte PS Zellen können jedoch multidifferenzierte Tumore 
bilden, sogenannte Teratome. Die Reduktion oder Eliminierung der Tumorigenität würde eine 
sichere Anwendung von Stammzellen bedeuten. Eine neu entwickelte Technik induziert frühe 
Keimzelleigenschaften in ES Zellen, die sogenannte gonogenic stimulated transition (GoST) 
induction. Die daraus entstandenen Zellen werden als GoST Zellen bezeichnet. In dieser 
Arbeit wurde die Möglichkeit der „GoST induction“ in murinen iPS Zellen und die 
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Tumorigenität der GoST Zellen im NSG Mausmodell untersucht. Obwohl GoST Zellen zur 
Teratombildung beitrugen, zeigten unsere Ergebnisse ein reduziertes Wachstum im Vergleich 
zu Wildtyp miPS Zellen. Durch Verlängerung der unstimulierten Kulturzeit von GoST Zellen 





1. Scope of Thesis 
 
1.1 Motivation 
In contrast to somatic stem cells, which are found in differentiated tissues and can only 
differentiate into specialized cell types of the tissue or organ, PS cells can differentiate into 
cells of all three germ layers. PS cells can be isolated and propagated indefinitely when 
cultured in vitro in contrast to somatic stem cells. The first PS cells of interest were 
embryonic carcinoma cells, but weren’t applicable in medicine due to their malign 
background. Human ES (hES) cells were the first PS cells considered as a cellular source for 
stem cell therapy in regenerative medicine, but were associated with several problems. These 
include ethical issues related to embryo destruction and immunocompatibility between donor 
and host. Autologous iPS cells are now considered to be a more reliable source of PS cells for 
therapeutic applications. iPS cells circumvent the immunological and ethical disadvantages of 
ES cells. Since iPS cells can be obtained by and re-transplanted into the same patient they 
share an identical genetic background and embryonic death can be avoided. The concept 
behind stem cell therapy is the differentiation of PS cells into progenitor cells prior to 
transplantation. The control over the differentiation process remains one of the most 
challenging tasks in stem cell therapy. Undifferentiated PS cells lead to multidifferentiated 
tumors when transplanted into an immunocompatible host. This type of tumor can be benign 
in form of a teratoma or malignant in form of a teratocarcinoma. But either way, tumor 
growth must be avoided at any point of a stem cell therapy. Different approaches to gain 
control over the differentiation process of PS cells have already been made. For example by 
introducing a suicide gene for PS cells in the genome, selecting differentiated cells via 
chemicals toxic for PS cells or cell sorting for undifferentiated cells. None of these techniques 
was able to reliably eliminate PS cells from differentiated cell populations until now. Gaining 
reliable and precise control over the differentiation process would lead to safer therapies 
involving stem cells and improve the understanding of the regulatory processes during 
differentiation of PS cells. 
In this context we investigated the tumorigenicity of a recently developed technology to 
induce early germ cell features in PS cells, the gonogenic stimulated transition (GoST) 
induction. The resulting cells are described as GoST cells. These cells hold the potential to 
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restore fertility in sterile men e.g. after chemotherapy or hereditary infertility. They also have 
the potential to be used for generating genetically modified organisms (GMO’s) such as mice 
or livestock. This might improve animal welfare in science and simplify the generation of 
GMO’s in contrast to classical methods such as embryo transfer or in vitro fertilization. We 
therefore adapted the GoST induction to culture conditions of murine iPS (miPS) cells with 
additional inhibiting factors in the culturing system. 
1.2 Objectives 
1.2.1 Objective 1 
The first objective was to translate the GoST induction from mES cells to miPS cells and 
characterize the pluripotency of an isolated miPS single cell clone compared to mES cells. 
Comparing the pluripotency of mES and miPS cells represents a necessary step if iPS cells are 
supposed to replace ES cells in regenerative medicine. Pluripotency includes the ability to 
differentiate into cell types of the three germ layers. Since iPS cells would circumvent host 
rejection as well as ethical issues, they are the most promising alternative to ES cells as a PS 
cell source for regenerative medicine. To apply PS cells in regenerative medicine it is of 
major importance to gain knowledge about migration and development of transplanted cells in 
the host. Previously, miPS cells were lentivirally transduced with the two reporter transgenes 
luciferase and the lactose operon LacZ. A single cell clone with high expression of reporter 
transgenes was selected for optimal detection of the cells in vivo. This made it possible to 
track and distinguish the transplanted cells from somatic cells in vivo. Evaluating differences 
between mES and miPS cells represents an important step for future experiments. Differences 
may influence experimental results and future miPS cell applications. 
In a previous work using mES cells, GoST cells showed enhanced multilineage differentiation 
potential and expressed markers of early male germ cells1. GoST cells may have potential as a 
stem cell source for regenerative medicine including fertility restoration in the male. Since 
pluripotency is correlated with tumor growth, the tumorigenicity of miPS-derived GoST cells 
had to be assessed. Another issue is the genetic stability of the cells during culture. Since 
genetic alterations of transplanted cells can harm either the patient or the offspring if 
introduced into the germline, karyotyping was performed, which however only can detect 
chromosomal abnormalities. Other analyses necessary to assess integrity of the genome, such 
as sequencing, were not performed here. 
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1.2.2 Objective 2 
Another objective was further characterization of the GoST induction. GoST induction 
represents a chemical treatment which showed the potential to generate gonocyte-like cells 
from PS cells with enhanced multilineage differentiation pathways1. GoST cells survive in 
culture conditions deprived of the antioxidant β-mercaptoethanol (βME) and leukemia 
inhibiting factor (LIF), which are prerequisite ingredients in PS cell culture systems. GoST 
cells show reduced cell proliferation rates and experience a G1/S phase arrest and express 
core pluripotency markers1. Unraveling further cellular mechanisms represents an important 
step of understanding GoST induction. The GoST induction had been applied to mES cells 
but not to miPS cells. Therefore the effect of the GoST induction on miPS cells had to be 
assessed. The use of new culture conditions with addition of the Sirtuin1 and DNA 
methyltransferase (DNMT) inhibitors raised the question if GoST induction can be translated 
to miPS cells. Thus the comparison of GoST induced miPS cells with non-GoST induced 
miPS (WT) cells was necessary to gain further knowledge about the differentiation-state of 
miPS-derived GoST cells. In this context we used several in vitro techniques including real-
time RT-PCR of mRNA and DNA as well as immunostaining and Western blot of 
pluripotency markers. 
1.2.3 Objective 3 
Introducing GoST cell-derived tissue or cells into the human body has to be safe. PS cells 
bear the risk of teratoma formation when transplanted into an immunocompatible host. GoST 
cells express pluripotency markers in vitro. Answering the question if GoST cells contribute 
to teratoma formation in vivo is an important step for future applications. Tumor growth 
during stem cell therapies embodies a major risk and prevents using PS cells therapeutically2. 
Therefore, we tested the tumorigenicity of GoST cells after seven days of GoST induction 
(D7) in comparison to WT miPS cells as positive control for PS cells. We chose the NSG 
mouse model for our in vivo experiments. NSG mice are amongst the most immunodeficient 
mouse strains to date and thus represent an ideal model for the transplantations of cells or 
tissues. This was a crucial part of this work, since GoST cells may help to restore fertility in 
the male through testis injections. A non-tumorigenic cell population is a prerequisite for any 





2.1 Embryonic stem cells 
Embryonic stem cells derived from the inner cell mass of blastocysts3,4. In vitro they 
proliferate indefinitely while retaining pluripotency to differentiate into the three germ layers. 
Pluripotency is defined by three main features: self-renewal, the ability to differentiate into all 
three germ layers and contribution to chimera formation when injected into a blastocyst5. 
When transplanted to an immunocompatible host in vivo, PS cells contribute to 
multidifferentiated tumors, described as teratoma. Teratoma formation is considered as an 
additional feature of PS and ES cells in vivo and is therefore used as an in vivo test for 
pluripotency6,7. The so called core pluripotency markers play an essential role for the self-
renewal of PS cells. NANOG, Oct4 and Sox28-12 are transcriptional factors, which mediate 
pluripotency. They code for the essential proteins that maintain pluripotency in PS cells. 
NANOG is a transcription factor that is crucial to maintain self-renewal13 and regulates the 
expression of other proteins involved in differentiation14,15. Oct4 and Sox2 form a binary 
complex to regulate the expression of certain genes15. Expression of pluripotency factors 
including NANOG, Oct4 and Sox2 is known to be linked to cancer16. Other factors like Klf4 
and c-myc also enhance the expression of core pluripotency markers17,18 but are known 
oncogenes as well19,20. Core pluripotency markers and their enhancers are not solely 
regulating pluripotency. The primed state of pluripotency represents the state of the post-
implantation epiblast21,22 and cells show different expression patterns of cellular markers in 
comparison to naïve pluripotency22. Primed PS cells are destined towards certain cell lineages 
and have limited abilities to contribute to a whole embryo. In contrast to murine ES (mES) 
cells which represent the naïve state of pluripotency, human ES (hES) cells, when cultured in 
vitro, enter the primed state of pluripotency unless the state of naïve pluripotency is 
genetically or chemically stabilized22. In vivo, hES cells correspond to the native state of 
pluripotency as cells of the inner cell mass of the blastocyst. Efforts have been made to reset 




2.2 Induced pluripotent stem cells 
Induced pluripotent stem (iPS) cells represent a great breakthrough in stem cell research. 
They were first derived from adult fibroblasts by reintroducing and overexpressing the so 
called Yamanaka factors Oct4, Sox2, Klf4 and c-Myc (OSKM) via retroviral gene transfer into 
the genome24,25. They then expressed Nanog26, Oct427, Sox2 and Klf428 similar to ES cells and 
showed similar growth characteristics25. The potential to differentiate into multiple cell 
lineages29-31 makes iPS cells a suitable replacement in stem cell research for ES cells. 
Although they share many characteristics with ES cells, they still differ in gene expression, 
DNA methylation32 and chromatin modification33. They circumvent ethical and 
immunological reactions compared to embryonic stem cells, since autologous transplantation 
of reprogrammed somatic cells avoids immunological responses. These cells can provide a 
reliable foundation for pharmaceutical research and clinical applications in humans. 
2.3 Germ cells 
Germ cells give rise to the gametes during the development of an organism. Primordial germ 
cells (PGC’s) are the first cells of the germ line34. PGC’s migrate through the embryo from 
the hindgut, over the dorsal cord to their final destination in the emerging gonads, which later 
develop into the testis in males and ovaries in females34-37. Germ cells express specific 
markers like stella (also Dppa3)38, Prdm1438, Cxcr439, Tex10140,41, TRA9842, Nanos2/343,44 or 
Dazl45 but also the pluripotency marker Oct446. A recent discovery showed the potential of the 
pluripotency factor Nanog to induce germ cell differentiation in blastocysts47, which indicates 
together with the Oct4 expression that germ cells share markers with PS cells. Tex101 and 
TRA98 are specific markers for germ cells in males. Tex101 appears on the cell membrane of 
prospermatogonia in immature seminiferous tubes of the fetal testis during gonadal 
development40,48 and plays an essential role in male fertility49. TRA98 is especially expressed 
in neonatal testis42. Blimp1, a zinc finger protein and transcriptional repressor gene, is another 
important marker of germ cells50 and hematopoietic stem cells51. PS and germ cells share 
similarities in expression patterns besides Oct452,53. Another important cellular feature of 
germ cells represents the demethylation of the genome50. Germ cells show a high degree of 
demethylation during their migration through the embryo, which enables genetic imprinting in 
the genome54-57. They finally migrate to the genital ridge and differentiate further into 
gonocytes and later into spermatogonia46. 
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2.4 Spermatogonial stem cells 
Spermatogenesis is maintained by spermatogonial stem cells (SSC’s). SSC’s either self-renew 
into SSC’s or commit to differentiation into spermatozoa58,59. They express Nanos260,61, 
promyeloic leukemia zinc finger (Plzf, also Zbtb16)62, GDNF59 and Gfra163. When cultured in 
vitro they grow as round cell colonies64,65. Gfra1 is a GDNF family receptor expressed in 
SSC’s63. Nanos2 is a unique protein only expressed in germ cells in the sexually determined 
male gonad66. It promotes the male germ cell differentiation while suppressing the female 
program simultaneously43. Repression of differentiation67,68 and meiosis43 through Nanos 2 is 
essential for maintenance of SSC’s61. Plzf is a zinc finger protein expressed throughout the 
embryogenesis, but also in the postnatal testis62. It controls the expression of lineage-specific 
target genes and thereby instructing cellular differentiation. Plzf knockout mice showed 
limited numbers of normal spermatozoa62,69. Damaged or dysfunctional SSC’s can lead to 
permanent infertility in men and often occurs after chemotherapy70,71. Restoring fertility is 
one of the major focuses of human reproductive medicine72. 
2.5 GoST cells 
A recent study investigated the effects of a chemical treatment to mES cells with the aim to 
introduce a proliferation arrest in absence of LIF and β-mercaptoethanol (βME) without the 
loss of cell viability. Usually deprivation from LIF and βME results in massive cell death of 
ES cells73. This culturing technology was described as gonogenic stimulated transition 
(GoST) induction1. The resulting cells were described as GoST cells. GoST induction 
includes a two-step chemical treatment. In a first step ES cells were conditioned by culturing 
ES cells in presence of the DNA methyltransferase (DNMT) inhibitor RG108 and the Sirtuin 
1 (Srt1) inhibitor EX527 while LIF and βME were still present for 10 passages1. This step 
aimed at mimicking the genome wide demethylation in PGC’s74. Resulting cells were 
described as conditioned ES (cES) cells. In the second step, the GoST induction, LIF and 
βME were removed from the medium and cES cells were cultured for seven days in presence 
of RG108, EX527 and tert-butylhydroquinone (tBHQ). tBHQ is an electrophilic redox-
cycling compound which induces Nrf2-dependent antioxidant responses75,76 and increasing 
intracellular reactive oxygen species (ROS) by undergoing redox cycling reactions77. 
Characterization of GoST cells revealed retained expression of the pluripotency markers 
Oct4, Nanog and Sox21. However, GoST cells reportedly expressed the germ cell related 
markers Nanos2, Tex101 and TRA981. Furthermore GoST cells showed enhanced cardiogenic 
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and hepatogenic differentiation1. Additionally Dax1, a transcriptional repressor of 
multilineage differentiation pathways78, showed downregulation in GoST cells during 
differentiation which has not been present in mES cells1. Thus, the question has been raised if 
GoST cells represent non-tumorigenic pluripotent stem cells for regenerative medicine. 
Approaches to eliminate tumorigenicity of PS cells usually interfere with the genome such as 
introducing a suicide gene for PS cells after differentiating into progenitor cells or tissues79,80. 
Alternatively, the potential of chemotherapy to eliminate PS cells after differentiation has 
been investigated81. Unlike these approaches the GoST induction aims at eliminating 
tumorigenicity in PS cells prior to differentiation. This distinct difference would make GoST 
induction a superior method for the generation of PS cells for regenerative medicine. The 
pluripotency of GoST cells together with germ cell-like features would make GoST cells an 
interesting cell source for clinical stem cell applications in reproductive medicine. Although 
GoST cells have been studied in vitro, the tumor formation potential remained unclear. As 
mentioned above, iPS cells can be a replacement for ES cells. Since GoST induction had been 
developed in murine ES cells and iPS cells require slightly different culture conditions, the 
question, if GoST induction can be performed on iPS cells was raised. 
2.6 Stem cells in regenerative medicine 
Since the discovery of PS cells from teratocarcinoma82 and the first cultivation of murine ES 
cells83, many approaches were made to develop stem cell therapies. The first successful stem 
cell therapy in humans was a bone marrow transplantation to cure a severe 
immunodeficiency84. Back then the doctors were not aware that they are transplanting 
hematopoietic stem cells85. With improving knowledge about stem cells and the recent 
discovery of creating iPS cells, treatments of yet incurable degenerative diseases might be 
possible86. In particular iPS cells would provide the best individual therapy for the patients. 
Especially in the field of neuroscience much effort is put into restoring the function of 
damaged or degenerated nerves e.g. in Huntington disease87, Alzheimer’s disease88,89 and 
Parkinson90 or treating brain cancer via stem cell therapy91,92. Tissues and organs with limited 
regenerative capacity such as muscle cells30,93,94, the eye95 and cartilage96 represent further 
fields addressed by applied stem cell therapy. In the liver, stem cell therapy could provide a 
valuable tool for treating cirrhosis, an irreversible destruction of liver tissue97. Recent 
discoveries suggested the possible recovery of fertility of sterile men using stem cell based 
approaches98-101. Stem cell therapies have shown promising results in animal models88,102 but 
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failed to translate into clinical trials to this day. The reasons range from legal and ethical 
issues regarding stem cell therapies in humans103 to serious immunological reactions such as 
the graft-versus-host-disease, which provokes host rejection even between identical twins104. 
Tumor formation is another concern regarding clinical trials of stem cell therapies105-108. For 
example the formation of teratomas, a multi differentiated tumor consisting of all three germ 
layers, represents a major risk for the patient when using PS cells in vivo2,107. Autologous 
transplantation of iPS cells circumvents many of the ethical and immunological issues of stem 
cell therapies including ES cells. With the recent discovery of the powerful gene editing tool 
CRISPR/Cas9109 the effectiveness of stem cell therapies can be raised. Genes edited with 
CRISPR/Cas9 could be tailored to each individual disease110. There have already been 
approaches to cure genetic diseases via CRISPR/Cas9 gene editing111. But again, those studies 
are so far only applicable in vitro111 or in animal models112 and have yet failed to progress into 
clinical studies for said reasons. 
Eliminating possible side effects of stem cell therapy is not the only challenge for clinical 
trials. For example there can be alterations in the chromosome set due to culturing and 
processing of stem cells prior to application113, which would lead to unpredictable side effects 
for the patient. This is especially dangerous if stem cells would be used in reproductive 
medicine, since damaged genomic DNA bares high risk for genetic diseases for further 
generations. Migration of stem cells should be avoided when injected to prevent metastasis in 
terminal vessel systems like lung, liver or kidney. Therefore, safe applications for stem cells 
in humans are not present until this day. 
Since stem cell therapies work well in animal models, the possibility of creating transgenic 
animals via testis injection is possible114. 
 
2.7 Teratoma 
Teratomas are benign tumors that contain differentiated cells from all three germ layers115-117. 
They are characterized by their rapid, mostly benign growth and heterogeneous mixture of 
tissues, such as hair, teeth, cartilage or skin118. Teratomas can transform into a malignant 
form, described as teratocarcinoma116 which then contains embryonic carcinoma cells117. 
Teratomas can occur spontaneously in vivo e.g. in testis119,120 or rarely in the spinal cord121,122 
or ovary123. When PS cells are transplanted into an immunocompatible host teratomas can 
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derive from PS cells105,106. Teratomas tend to not infiltrate surrounding tissue but can form 
metastasis in rare cases124,125. 
Since PS cells contribute to teratoma formation, the teratoma assay is used to evaluate the 
pluripotency of cells. Teratoma formation is declared as one of the key features of pluripotent 
cells118,126. Immunocompromised mouse models such as NSG or Nu/Nu represent ideal hosts 
for transplantation experiments and are therefore widely used for teratoma formation assays6. 
Teratoma formation does not only occur in the same species environment, but in cross-species 
transplantation as well127. 
Thus, teratoma formation is not only a valuable tool to evaluate the so called “stemness” of 




3. Materials and methods 
 
3.1 In vitro methods 
3.1.1 Cell culture 
Murine embryonic stem cells (mES cells) were purchased from Merck Millipore AG, 
Switzerland (Millipore, SCC050). mES cells that expressed the transgenes luciferase and lacZ 
were purchased at Applied Biological Materials Inc. (Richmond, Canada). The lentiviral 
vectors for lacZ and luciferase are displayed in the supplements (S1 and S2). The murine 
induced pluripotent stem cells (miPS cells) as well as the transgenic miPS cells (miPS 
Luc/Lac) were purchased at Applied Biological Materials Inc. (Richmond, Canada) and were 
virus free reprogrammed by the company. The plasmid sequences for Oct4, c-myc and Klf4 
are displayed in the supplements (S3 and S4). The transgenic cells were additionally equipped 
with a puromycin resistance gene (S4). 
Murine embryonic fibroblasts (mEF) derived from FN-floxed murine embryos were kindly 
provided by Reinhard Fässler (Max Planck Institute of Biochemistry, Martinsried, Germany). 
The isolation of the cell clones miPS Luc/Lac clone 5 (miPS clone 5) and mES Luc/Lac 
Clone 11 (mES Clone 11) was performed by Cameron Moshfegh (Laboratory of Applied 
Biomechanics, ETH Zürich, Switzerland) by single cell isolation and selected for expressed 
transgenes prior to this study. miPS Luc/Lac cells were diluted and seeded in 96-well plates. 
96-well plates were then checked for single cells in each well and cultured for several days. 
For culturing mES and miPS cells EmbryoMax® ES Cell qualified DMEM (Millipore, 
SLM220-B) was used as basic medium (BM). The basic growth medium (BGM) contained 
15% v/v. of Embryomax® ES qualified fetal bovine serum (Millipore, ES009-C), 1 mM of 
minimal essential sodium pyruvate solution (Millipore, TMS-005-C), 0.1 mM of non-
essential amino acids (Life Technologies, 11140-035) and 2 mM of GlutaMAX™ supplement 
(Life Technologies, 35050-038). For culturing mES and miPS cells 0.1 mM of β-
mercaptoethanol (βME, Life Technologies, 31350-010), 1000 units/ml of LIF (Leukemia 
inhibitory factor, EMD Millipore, ESG1106), 1 µM of CHIR99021 (Cayman Chemicals, 
13122), 1 µM of PD0325901 (Sigma Aldrich, PZ0162) and for transgenic cells 0.5 µg/ml of 
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puromycin dihydrochloride (Invitrogen, A11138-03) were added to BM (2iL or 2iL + puro 
respectively). 
mEF cells were cultured in 1x DMEM plus GlutaMAX™ (Gibco by Life Technologies, 
21885-025) with 9 % v/v of fetal bovine serum (BioWest, S181H). 
All cells were stored in a humid environment at 37°C and 5% CO2 in an incubator. mES, 
miPS and mEF cells were passaged by volume 1:10 – 1:30 every two to three days at around 
70-90% confluence. Cells were cultured in T25/T75 cell culture flasks (TPP, Thermo Fischer 
Scientific, Switzerland 90026/90076), 6-well plates (TPP, Thermo Fischer Scientific, 
Switzerland 92006) or µ-Slide 8-well dishes (ibidi, Germany 80826). The plates were 
incubated for 10 minutes with EmbryoMax® 0.1% gelatin solution (Millipore, ES-006-B), 
except for mEF cells, then the gelatin was removed and the cell suspension was added. Cells 
were dissociated after incubation for 10 minutes with StemPro® Accutase® Cell dissociation 
reagent (Invitrogen, A11105-01). The Accutase® reaction was neutralized by adding equal 
amounts of medium. The cell suspension was centrifuged at 1100 rpm in 15ml Falcon®-tubes 
for 3 minutes at room temperature. The supernatant was removed and the cell pellets were 
resuspended in respective media. The centrifugation step was repeated and then cells were 
diluted with the particular dilution factor in the respective media and added to the new 
flask/dish. For cell counting, 10 µl of cell suspension was diluted 1:10 in medium and 10 µl of 
the diluted suspension was pipetted to a Neubauer improved cell counting chamber and cells 
were counted using a phase contrast microscope at 20x magnification. 
For cell freezing, cells were cultured in T25 or 6-well dishes for two days. They were then 
dissociated with Accutase®, washed twice in the respective medium and then diluted in 
CryoStor®CS10 (Stemcell Technologies™, 07930) cell freezing medium at 106 cells/ml in 
Cryo.S™ cryotubes (Greiner bio-one, 123 2XX). Cells were then stored in liquid nitrogen. 
 
 
3.1.2 GoST induction series 
For the GoST induction series only miPS clone 5 cells were used. Cells were seeded at 20’000 
cells/cm2 in 8-well ibidi dishes for immunofluorescence, 3 wells of one 6-well dish in 
triplicates for real-time RT-PCR and in three T25 flasks for Hematoxylin & Eosin (H&E) 
staining of cell-pellets. The series contained two groups. The first group consisted of miPS 
clone 5 cells that underwent GoST induction (GoST cells). The second were miPS clone 5 
12 
 
(WT) cells that did not undergo the GoST induction as a negative control. In the first group, 
miPS clone 5 cells were cultivated in 6-well dishes over 10 passages in 2iL + puro with 
additional 5 µM of Ex527 (Cayman Chemical Company, 10009798) and 100 µM of RG108 
(Cayman Chemical Company, 13302), both diluted in cell culture grade dimethyl sulfoxide 
(DMSO, Applichem, A3672,0100). The resulting cells were described as conditioned miPS 
clone 5 (cmiPS clone 5) cells. In the second group, WT cells were cultured in a T25 flask with 
2iL + puro plus 0.1 µl/ml DMSO for 10 passages. These cells were described as WT cells. 
After 10 passages the complete medium of cmiPS cells was changed from 2iL + puro plus 
Ex527 and RG108 with BM with added EX527, RG108 (in unchanged concentrations) and 10 
µM tert-butylhydroquinone (tBHQ, Sigma-Aldrich, 112941-5G). cmiPS cells were cultured 
under these conditions for seven days without splitting, but exchanging the media every 10-
16h. The cmiPS-derived cells were described as GoST cells after the seven days. Culturing of 
WT cells was synchronized by starting at a later time point. After the conditioning step, the 
cmiPS cells were seeded into 8-well ibidi dishes for immunofluorescence and 6 well plates for 
mRNA isolation. WT cells were seeded into 8-well ibidi dishes and 6 well plates after 10 
passages. Then the media of both WT and GoST cells were exchanged completely with BM 
plus 0.1 mM βME for additional 20 days. In those 20 days the volume of medium was raised 
to 600 µl/well in 8-well ibidi dishes and 6 ml/well in each well of the 6-well dishes. The 
covers of the 8-well dishes were removed and the dishes were put in a 137 mm round cell 
culture dish (TPP, 93150 2/3). 400 µl of medium of a total volume of 600 µl were changed 
twice per day in the 8-well dishes after 12-16h incubation time in the morning and 8-12h in 
the evening. In the 6-well dishes 4ml of medium of a total volume of 6 ml were changed twice 
per day after 12-16h in the morning and 8-12h in the evening. In the T25 flasks the volume of 
the medium was raised to 8 ml total and 6 ml of medium was exchanged twice per day after 
12-16h incubation time in the morning and 10-12h in the evening. The cells were harvested 
for RNA isolation and fixed for immunofluorescence at specific time points. For GoST cells 
the starting point was the start of the GoST induction (Conditioned D0) and after the 7 days of 
GoST induction every 4 days, starting with GoST D7 following GoST D7+4, GoST D7+8, 
GoST D7+12, GoST D7+16 and GoST D7+20. Harvesting of WT cells started at the day of 
medium exchange from 2iL + puro plus DMSO starting with WT D0 following WT D0+4, 
WT D0+8, WT D0+12, WT D0+16 and WT D0+20. From harvesting points GoST D7 and 
WT D0+4 on cells were harvested with a cell scraper due to their adhesiveness. The scraped 
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cells were diluted in 5 ml 1x PBS pH 7.4 (Gibco® by Life Technologies, 10010-015) and 
centrifuged at 1100 RPM. Then the supernatant was discarded and the pellet was resuspended 
in 1 ml of PBS and centrifuged again. The resulting cell pellets were used for RNA isolation. 
For fixation, the complete medium of each well was removed and the cells were washed twice 
with 1x PBS, then fixed with 2.5% Formaldehyde in PBS for 10 minutes. The Formaldehyde 




Fixed cells in 8-well ibidi dishes were washed once with PBS and permeabilized with 0.3% 
Triton X-100 (Sigma, T8787-50ML) in PBS for 10 minutes at room temperature (only for 
intracellular staining) and washed again once with PBS. Then they were blocked for 1h with 
3% bovine serum albumin (BSA, Sigma, A4503-50G) in PBS at room temperature. Samples 
were then incubated with the primary antibody, diluted in 3 % BSA, overnight at 4°C. The 
primary antibodies were anti-Nanog (0.5 mg/ml, 1:200, mouse, BD Biosciences, 560259), 
anti-Sox2 (1 mg/ml, 1:200, mouse, Millipore, MAB4343), anti-TRA98 (1 mg/ml, 1:200, rat, 
Abcam, ab82527), anti Oct4 (1 mg/ml, 1:200, rabbit, Abcam, ab19857), anti-SSEA1 (1 
mg/ml, 1:200, mouse, Millipore, MAB4301), anti-Gfra1 (1 mg/ml, 1:200, rabbit, Santa Cruz, 
sc10716), anti-firefly luciferase (1 mg/ml, 1:200, mouse, Abcam, ab16466). Then cells were 
washed once with 1x PBS for 5 minutes and, if necessary, washed twice for 5 minutes with 
0.1% Triton X-100 in PBS. Then they were washed again twice with PBS for 5 minutes. 
Afterwards the cells were incubated with the secondary antibody, diluted in 3 % BSA for 1h 
at room temperature. The secondary antibodies were anti-mouse IgG conjugated to Alexa 
Fluor 488 (2 mg/ml, 1:400, donkey, Life Technologies, A-21202), anti-rat IgG conjugated to 
Alexa Fluor 546 (1 mg/ml, 1:200, goat, Molecular Probes, A11081), anti-rabbit IgG 
conjugated to Alexa Fluor 555 (1 mg/ml, 1:200, goat, Invitrogen, A-21429), anti-mouse IgG 
conjugated to Alexa Fluor 633 (1 mg/ml, 1:200, goat, Invitrogen, A-21052), anti-rabbit IgG 
conjugated to Alexa Fluor 647 (1 mg/ml, 1:200, goat, Life Technologies, A-21245) and anti-
rat IgG conjugated to DyLight™ 649 (1 mg/ml,1:200, donkey, Jackson Immuno Research, 
712-495-153). Then the cells were washed once with PBS for 5 minutes and for intranuclear 
staining twice with 0.1% Triton X-100 for 5 minutes. Nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI, Sigma, 28718-90-3) at a dilution of 2.5µg/ml for 10 
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minutes. Cells were mounted using ProLong® Gold Antifade Mountant (Life Technologies, 
P10144) and covered with an approximately 9x9 mm microscope cover glass cut from a 
18x18 mm microscope cover glass No. 0 (Marienfeld, 0100032) and dried at room 
temperature overnight inside a drawer. For TRA98 staining all incubation times were 
doubled. 
Imaging was performed with a Leica TCS SP5 confocal microscope (Leica, Microsystems, 
Mannheim, Germany). DAPI was excited with a 405nm laser with gain from 500-700V and 
emission was detected between 425-480nm. Alexa Fluor 488 was excited with a 488nm laser 
with gain between 736-850V and emission was detected between 505-550nm. Alexa Fluor 
546 was excited with a 561nm laser with gain of 700V and emission was detected between 
571-600nm. Alexa Fluor 555 was excited with a 561nm laser with gain of 901V and emission 
was detected between 571-605nm. Alexa Fluor 633 was excited with a 633nm laser with gain 
of 908V and emission was detected between 643-670nm. Alexa Fluor 647 was excited with a 
633nm laser with gain of 725V and emission was detected between 653-695nm. For 
excitement of Dylight™649 a 633nm Laser was used with gain of 900V and emission was 
captured between 656 and 690nm. Images of luciferase were taken with a 20x air objective. 
All other images were taken with a 63x PL APO CS 1.4 oil objective. For analysis and 
optimization of images taken ImageJ, Adobe® Illustrator CS6 and the Leica LASAF software 




3.1.4 Light microscopy 
For light microscopy mES, miPS, miPS clone 5, mEF and the GoST series cells were cultured 
either in 8 well dishes or T25 flasks. The medium of the cells was completely removed and 
cells were washed twice with 1x PBS, then fixed with 2.5% Formaldehyde for 10 minutes. 
Afterwards the Formaldehyde was exchanged with 1x PBS and cells were kept at 4°C in a 
refrigerator until imaging. For light microscopy an Axiovert 200M inverted microscope (Carl 
Zeiss, Jena, Germany), with either 10x Plan-Neofluar 0.3 Ph1 or 20x LD Plan-Neofluar 0.4 
Ph2 objectives was used. For analysis and optimization ImageJ, Adobe® Illustrator CS6 and 
the AxioVision Rel. 4.8 software were used. Size and brightness of the pictures were altered 





3.1.5 Luciferase assay 
For the Luciferase assay miPS Luc/Lac and miPS clone 5 cells were thawed and cultivated in 
4 wells of an 8-well dish each at a density of 34’000 cells/cm2 with 2iL + puro for two days. 
Cells were then treated with the Luciferase Assay System with Reporter Lysis Buffer 
(Promega, E4030) according to the manufacturer’s protocol. Analysis was performed using a 
Tecan Infinite M200 (Tecan, Switzerland). Readouts were analyzed using Microsoft Excel. 
 
 
3.1.6 X-Gal staining 
For X-Gal staining miPS Luc/Lac and miPS clone 5 cells were cultivated in two wells of an 8-
well dish each, at approximate 34’000 cells/cm2 cell density in 2iL + puro for 2 days. Then 
media were removed completely and cells were washed three times with 1x PBS. The X-Gal 
staining was conducted according to the manufacturer’s manual. Images were taken with the 
Axiovert 200M inverted microscope with 10x air and 20 x air objectives with 59ms exposure 
time for 10x images and 41ms (miPS clone 5) and 30ms (miPS Luc/Lac) exposure time for 
20x images. Images were analyzed and optimized using ImageJ and Adobe® Illustrator CS6. 




3.1.7 Real-time PCR analysis 
Total RNA was isolated from ~ 1x106 cells per sample using the RNeasy Mini Kit (Qiagen, 
74104/74106) with RNAse free DNAse treatment (Qiagen, 79254), following the 
manufacturers manual. RNA concentration was measured with a NanoDrop 2000 UV-Vis 
Spectrophotometer (Thermo Scientific). Isolated RNA was stored in 500 µL RNase-free tubes 
provided by the kit at -20°C. 
After measurement of RNA concentration, RNA was diluted to a total amount of 2 µg or 1 µg 
in 15 µl in Nuclease-free water (Life Technologies, 10977-035) into 500 µl thin walled 
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Eppendorf PCR tubes (Eppendorf, 0030124537). For reverse transcription (RT) 2 µg total 
RNA was reverse transcribed into cDNA in a reaction volume of 20 µl using the iScript™ 
Advanced cDNA Synthesis Kit (Bio-Rad, 1708842). Each RT reaction mix contained 4 µl 5x 
iScript advanced reaction mix and 1 µl iScript advanced reverse transcriptase. The 20 µl 
reactions were incubated in an Eppendorf Mastercycler (Vaudaux, Switzerland) at 42°C for 
30 minutes, at 85°C for five minutes and held at 4°C. The resulting cDNA was then diluted 
1:10 (2 µg samples) or 1:5 (1 µg samples) in nuclease-free water and stored at -20°C. 
DNA was isolated from mES, miPS Luc/Lac, miPS clone 5 and mouse tissues (ear-punches, 
liver, lung, spleen, tumor) with the DNeasy blood and tissue kit (Qiagen, 69504/69506) 
following the manufacturers protocol (page 28-30). For liver, lung and spleen samples an 
additional amount of 20 µl of Proteinase K was added and the incubation time of Proteinase K 
digestion was extended to 24h. For the digestion step, samples were put in an Eppendorf 
Thermomixer for 24h at 500 rpm. DNA concentration was measured using the NanoDrop UV 
Spectrophotometer. Samples were stored in 1.5 ml Eppendorf tubes at -20°C. 
DNA and cDNA for real-time RT-PCR analysis were diluted 1:10 in nuclease-free water. The 
Master mix for each reaction contained 10 µL SsoAdvanced™ SYBR® Green Supermix 2x 
(BioRad, 172-5262), 5 µL sample with a total amount of 5 ng cDNA, 3.8 µL nuclease-free 
water, 0.6 µL forward primer and 0.6 µL reverse primer to a total volume of 20 µL. PCR 
reactions were performed in Hard-Shell® Low-Profile Thin walled 96-Well Skirted PCR 
plates (Bio-Rad, HSP-9602). Primers were designed using PrimerSelect from the Lasergene 
software suite (DNASTAR, Madison, WI). All primers were synthesized at Microsynth 
(Mycrosynth, Balgach, Switzerland). Gene abbreviations, NCBI reference, amplicon size and 
primer sequences are indicated in table 1. 
 
Table 1 






Forward Primer Sequence 
5’  3’ 
Reverse Primer Sequence 
5’  3’ 
Species 
Reference Genes 
Tbp NM_007393 265 GCTGTATTCCCCTCCATCGTGG CACGGTTGGCCTTAGGGTTCAG Mus 
musculus 
Gapdh NM_008084 90 ACCCCCAATGTGTCCGTCGTG AGATGCCTGCTTCACCACCTTCTTG Mus 
musculus 
Core Pluripotency Markers 
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Esrrb NM_011934 262 TGCCCGGGACCCAAGAGACATA AGTGAGTTCCGGCTGGCTGAGGT Mus 
musculus 




Naïve Pluripotency Markers 
Prdm14 NM_00108120
9 
113 CGCCACCACCGAGGAGGAGT CCGGGTTCAACAAGGGAGCAGT Mus 
musculus 




Stra8 NM_009292 130 CAGCGCTATGTTTGCCACCTGC TGGGGGCTCTGGTTCCTGGTT Mus 
musculus 




















Germ cell Markers 








Ddx4 NM_010029 100 AACGCCAAACCCTTTTATTCAGT TGCCCAACAGCGACAAACAAGTAA Mus 
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GCTAC CT musculus 
Zbtb16 NM_00103332
4 
86 CCGCCCATTTTTACCCCCTACAA ACCCCAGCCCATATCCTCTCAACA Mus 
musculus 












Spermatogonial stem cell Markers 
Gfra1 NM_00128545
7 




136 ATGCCCGCCTGCCTGTAAAGTG ATGCCGGGGTAGGGGTTCAGAC Mus 
musculus 












Tyrobp NM_011662 77 GAGCCCTCCTGGTGCCTTCTGTT TCACTCTGGGCCTGTACGGGACTTA Mus 
musculus 
































Real-Time RT-PCR reactions were performed on DNA and cDNA using CFX Connect™ 
Real-time PCR Detection System (Bio-Rad). PCR reactions were incubated at 95°C for 3 
minutes, followed by 39 cycles of 95°C for 10 seconds and 62°C for 30 seconds and were run 
as triplicates of three independent experiments. Cycling protocols, plate setups and master 
mix were designed using the BioRad CFX Manager 2.1 software (Bio-Rad). Readouts were 
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analyzed and optimized using Microsoft Excel and BioRad CFX Manager 2.1. mRNA 
expression levels relative to Gapdh and Tbp were calculated based on the ΔΔCt method. 
Statistical analysis was conducted using the ANOVA shiny app for a One-Way ANOVA 
(http://shiny.stat.tamu.edu:3838/hassaad/SumAOV1/). For ANOVA analysis the standard 
error of the mean (S.E.M.) and a Tukey/Kramer test were used. 
 
 
3.1.8. Western blot analysis 
For Western blot analysis mES, miPS and mEF cells were cultured in triplicates under 
standard culture conditions in three wells of a 6-well dish for each cell line. After two days 
the medium was removed and cells were washed twice with PBS. Then freshly mixed RIPA 
buffer (Sigma-Aldrich, R0278) combined with both protease and phosphatase inhibitors 
(Sigma-Aldrich) were added. The dishes were incubated for 5 minutes on ice. Cells were then 
scraped from the surface with a cell scraper and cell lysates were pipetted into an Eppendorf 
tube on ice. Samples were then centrifuged for 10 min at 10’600g. The supernatant was 
pipetted into another Eppendorf tube and 20 µL of the supernatant was stored at -20°C for 
protein concentration measurement using the Pierce BCA protein assay (Thermo Scientific, 
23225). Afterwards the exact volume of remaining supernatant was measured and incubated 
with 5x Laemmli buffer for 5 minutes at 95°C with an Eppendorf Thermomixer. Samples 
cooled down to room temperature on a bench and were then stored at -20°C until blotting. 
Samples were loaded with 10 mg/well, fractionated by a 6% stacking gel and 10% running gel 
SDS-PAGE and transferred to a methanol activated polyvinylidene difluoride (PVDF) 
membrane. The membrane was incubated in 10x Roti®-Block (Roth, A151.1) TBS-T buffer 
overnight at 4°C in a 50 ml tube on a multi-axle-rotary-mixer CAT-RM5 (Ingenieurbüro M. 
Zipper GmbH, Staufen, Germany) with the primary antibody. The primary antibodies were 
anti-Nanog (1:1000, mouse, BD Biosciences, 560259), anti-Oct4 (1:1000, rabbit, Abcam, 
ab19857), anti-Sox2 (1:1000, mouse, Millipore, MAB4343) and ɑ-tubulin (1:1000, mouse, 
Abcam, ab7750). The membrane was washed three times with tap water, once with TBS-T for 
10 minutes, blocked with Roti® buffer and incubated with the secondary antibody for 1h at 
room temperature. The secondary antibodies were anti-rabbit horse radish peroxidase 
(Jackson ImmunoResearch Laboratories, 1:2000, donkey, 711-035-152), anti-mouse alkaline 
peroxidase (Promega, S3721, 1:2000) and anti-mouse HRP (Jackson ImmunoResearch 
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Laboratories, 1:2000, donkey, 715-035-150). Blots were further developed following the 
manufacturer’s protocol using ECL plus substrate (GE Healthcare, Piscataway, NJ, USA) or 
CDPstar substrate (Sigma-Aldrich, C0712). Blots were developed in a darkroom on Fujifilm 
Super RX medical X-Ray film 100NIF 18x24 (Fujifilm, 47410 19236). Films were scanned 
and analysis was performed with ImageJ and Microsoft Excel. 
Western blot experiments were conducted under supervision and aid from Lina Aires 
(Laboratory of Applied Mechanobiology, ETH Zurich). 
 
 
3.1.9 Chromosome painting 
For Chromosome painting mES, miPS and miPS clone 5 cells were cultured under standard 
culture conditions in one well of a 6-well dish each. Cells were scraped from the surface and 
transported in BGM to Claude Schelling (Clinic of Reproductive Medicine, Animal Genetics 
Group, Vetsuisse-Faculty University of Zurich) and Dr. eng. Aldona Pieńskova-Schelling 
(Institute of Genetics, Vetsuisse-Faculty University of Bern, Bern, Switzerland). 
Alive mouse cells were arrested in the metaphase stadium by adding the Colcemide (0.5 ml 
for each 10 ml of culture medium) for 2h. After delicate centrifugation (800 rpm, 8 min, 
+24°C) and removing the supernatant hypotonic KCl solution (0.075M, +37°C) was added by 
slow dropping till 6 ml and then cells were incubated 20- 25 min at +37°C. After incubation, 
centrifugation and removing the supernatant the fixation of cells was performed by slow 
dropping a frozen (-30°C- -80°C) Carnoy fixative (absolute methanol and glacial acetic acid 
in proportion 3:1) until 8ml, centrifugation at +4°C, 800 rpm, 8 min, then after removing the 
supernatant again the fixative was added until 4ml. The chromosome suspensions were 
concentrated to 100 µl and 10 µl of it were dropped onto cold, wet microscope slides. Slides 
were cleaned in the detergent before usage, rinsed in distilled water and incubated in 2N HCl 
for 2-3 days. Then rinsed again in distilled water and stored in the absolute ethanol at -20°C. 
All materials were dropped at one place that the surface area was not bigger than Ø 15mm. 
The microscopic preparations were prepared 24h before hybridization and incubated in this 
time in dry environment at +37°C. The hybridization was carried out for 18-24h. 
In a first step RNA was digested by reaction with RNAse A (100-120 μl RNA-se from 
working solution: 25 μl RNA-se A 10mg/ml + 2.475 ml 2x saline-sodium citrate buffer (SSC) 
which was carried out in humid environment for 1h at +37°C. After incubation, slides were 
21 
 
rinsed in a 2x SSC at room temperature, 3x for 2.5 min and then dehydrated by incubation in 
the ethanol row 70%-80%- 90% for 2.5 min in each concentration at room temperature. Next 
steps were carried out exactly according to the manufacturer’s instructions from Chrombios 
(Nussdorf, Germany) multi-color FISH (http://wp.chrombios.de/about-fish/multi-color-fish/). 
For image acquisition, the microscope Axio Imager Z1and the MetaSystems software 
ISIS/IKAROS was used. 
 
 
3.2. In vivo methods 
 
3.2.1. Teratoma formation assay 
One of the main goals of this study was to evaluate the tumor growth potential of miPS- 
derived GoST cells. The gold standard to assess the potential tumor growth is the teratoma 
assay. PS cells proliferate in vivo into multi lineage differentiated tumors, called teratoma, 
that consist of all three germ layers when transplanted into an immunocompatible host. For 
our teratoma assay we chose the NSG mouse model since it represents one of the most 
immune compromised mouse strains and therefore was ideal for transplantation experiments. 
WT and GoST cells were derived from miPS clone 5 cells.  
The teratoma formation assay was conducted under the animal license number 166/2014. For 
the teratoma formation assay 16 weeks old female white NSG mice (NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ, Charles Rivers, Saint-Germain-Nuelles, France) in six groups with 
five mice per group were used. The animals were held at 21°C (+/-1°C) and 50% rel. 
humidity (+/- 10%) in individual ventilated cages (IVC’s) Type II long (Fa. Bioscape, 
Emmendingen, Germany) with LIGNOCEL select bedding (Fa. JRS, Rosenberg, Germany) in 
IVC rack systems. The mice were fed with autoclaved pellets for mice and rats (Fa. Kliba 
Nafag, Kaiseraugst, Switzerland) and watered with acidified and autoclaved tap water to a pH 
between 2.75 and 3.5. For acidification 25% sulfuric acid was used. Identification of each 
mouse was facilitated by earmarks from one to five for each cage. Ear punches were collected 
for DNA isolation and subsequent Real-Time PCR analysis. Injected cells consisted of GoST 
cells D7 or WT cells D0 respectively in two T75 flasks each. The preparation of the cells was 
provided by Dr. Cameron Moshfegh (Laboratory of Applied Mechanobiology, ETH Zurich). 
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Cells were dissociated, washed and resuspended in a 1:1 Corning® Matrigel® hESC-qualified 
matrix (Corning, 354277) PBS mixture containing either 102, 104 or 3*106 cells on ice for 
each group of 5 mice. Mice were previously shaved and injected under 2.5 Vol% Isoflurane 
volatile anesthesia (Attane™, Primal Healthcare Limited, India) on a heating pad at 37°C with 
100µL of the Matrigel/PBS/Cell mixture subcutaneously into the upper left abdominal wall 
approximately 5mm laterally from T12-L2 vertebrae, near the caudal end of the ribcage. Two 
mice had to be injected into the right upper left abdominal wall due to previous injection 
errors. Mice were put back into their cages after waking up and were observed three times a 
week on behavior, habitus and eventual tumor growth for 13 weeks. Additionally, once per 
week each mouse was taken out of the cage and examined individually, including palpation of 
the injection site and measurement of the tumor growth using a sliding caliper. If the tumor 
diameter gained over 15mm in diameter and/or the behavior of a mouse was heavily impaired 
by the tumor growth, the mouse had to be sacrificed. End points for each mouse were 
determined by a score sheet (S5 and S6). Mice that reached the end point were discharged 
separately in individual cages from the animal facility followed by IVIS imaging. 
 
 
3.2.2 IVIS Imaging 
Discharged mice were weighted and injected with a dosage of 150 µg/kg bodyweight of 
optimized D-Luciferin (Perkin Elmer, 122796) intraperitoneally. After 5 - 10 minutes the 
mice were put into Isoflurane 2.5 Vol% volatile anesthesia and put into the IVIS. Prior to the 
IVIS imaging process, the region around the tumor was shaved. The mice were kept under 
anesthesia during the whole imaging process. Pictures were taken with a binning factor of 2 
and an exposure time of 1 sec with a delay of 1 min between each consecutive image. Four 
pictures were taken for each mouse. Immediately after the imaging process each mouse was 
sacrificed by cervical dislocation while still under anesthesia. Immediately afterwards blood 
was drawn from the heart with an EDTA wetted syringe and stored in an Eppendorf tube. The 
corpses were put on ice and after every mouse was imaged a dissection was performed on 
each mouse. At first, the abdominal cavity was opened and liver, spleen, kidney and ovaries 
were removed. For liver samples tissue from the Lobus lateralis dexter was taken. For Spleen 
samples a part of the cranial pole was taken. Tissue from the kidney was obtained from half of 
the left kidney. Afterwards the chest was opened and lung and heart were extracted from the 
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body and parts of the organs were stored at -80°C. For lung samples a part of the Lobus 
cranialis sinistri was collected. Samples from the heart were obtained from the caudal apex of 
the heart. Then, bone marrow from the right femur was extracted. In the end the skin with the 
tumor was removed and parts of the chest skin and tumor were stored. All samples were 
stored at -80°C. The remains of the mice were fixated in neutral-buffered 10% formalin. 
Tumor parts for histological analysis were incubated in formalin for 48 hours and then the 
formalin was exchanged for 1x PBS. All fixated samples were sent to a pathologist for 
histological analysis. For some mice, parts of the organs were frozen in O.C.T.™ compound 
(Sakura Finetec Europe B.V., 4583) and stored at -80°C for histological analysis. 
 
 
3.2.3 Tumor pathology and histological analysis 
Tumor pathology and histological analysis was conducted by Giovanni Pellegrini at the 
Laboratory for Animal Model Pathology (LAMP, Vetsuisse Faculty University of Zurich). A 
complete necropsy, including a thorough external and internal gross post mortem examination 
was performed on each mouse. The injection site area, including the subcutaneous mass and 
the adjacent skin, was sampled and fixed in formalin for histological examination. After 48 h 
fixation in formalin, the masses from all animals were trimmed through their longitudinal 
axis, dehydrated in graded alcohol and routinely paraffin wax embedded. Sections (3-5 µm 
thick) were prepared, mounted on glass slides, deparaffinized in Xylene, rehydrated through 
graded alcohols and stained with Haematoxylin and Eosin (HE) for the histological 
examination. In a few mice euthanized in the early phases of the experiment, the masses were 
entirely frozen using liquid nitrogen and stored at -80°C. These were evaluated by an 
European College of Veterinary Pathologists (ECVP)-certified veterinary pathologist in a 
blind fashion.  
For histological analysis, the slides were scanned with a Hamamatsu NanoZoomer-XR Digital 
slide scanner (C12000, Hamamatsu Photonics, Hamamatsu, Japan) and analyzed using the 








4.1 miPS clone 5 expresses core pluripotency markers and the introduced transgenes 
Since it has been shown that mES and miPS cells differ in expression patterns32 our aim was 
to evaluate the expression of pluripotency factors in ES and iPS cells. The GoST induction 
has been established for mES cells1, but not for miPS cells. Significant differences in 
pluripotency of mES and miPS cells potentially influence the outcome of the GoST induction. 
The germ cell-specific marker TRA98 was compared between mES and miPS clone 5 since 
the GoST induction induces gonocyte-like cells in mES cells. The isolated miPS clone 5 was 
selected from miPS Luc/Lac cells for expression of the introduced transgenes and did show 
the highest level of all isolated miPS Luc/Lac clones. Therefore miPS clone 5 represents the 
ideal cell clone in terms of reporter gene expression for this study (Fig. 1 and Fig. 2). We used 
mEF cells as a negative control for pluripotency since mEF cells represent differentiated cells 
and thus we did not expect expression of pluripotency factors. 
The results of real-time RT-PCR confirmed that mES and miPS clone 5 cells did express the 
majority of core and naïve pluripotency markers without significant differences (Fig. 1 and 2). 
The expression of the core pluripotency markers Nr5a2 and Tbx3 showed significant 
differences between mES and miPS clone 5 cells (Fig. 1). Notably the essential pluripotency 
markers Nanog, Oct4, Sox2 and Klf4 were evenly expressed with no significant differences in 
mES and miPS clone 5 cells on mRNA expression levels. Expression of naïve pluripotency 
markers showed significant differences for Dax1, Dazl, Stra8 (Fig. 2) between mES and miPS 
clone 5 cells. mES cells showed higher expression for Dazl and Stra8 compared to miPS 
clone 5 cells, while miPS clone 5 cells showed higher expression of Dax1 compared to mES 
cells. mEF cells did not express most of the core and naïve pluripotency markers (Fig. 1, 2). 
Analysis of the western blots showed significant differences in Oct4 and Sox2 expression 
(Fig. 3A) between mES and miPS clone 5 cells. mEF cells showed significant lower 
expression for Nanog, Oct4 and Sox2 (Fig. 3A). The blots showed a fading signal towards 
one side of the gel for Nanog, α-tubulin and Oct4 (Fig. 3B). 
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Immunofluorescence confirmed the previous findings. mES and miPS clone 5 cells did 
express the core pluripotency markers Nanog, Oct4 and Sox2 and the naïve pluripotency 
marker SSEA1 (Fig. 4). miPS clone 5 cells showed a brighter signal for Nanog and SSEA1 
compared to mES cells. The Nanog signal in miPS cells was more heterogeneous compared to 
mES cells though. The TRA98 staining showed heterogeneity in mES and miPS clone 5 cells 
(Fig. 4). mEF cells did not express any of the investigated markers in the 
immunofluorescence. 
The last goal of characterizing the miPS clone 5 cells was the confirmation of the expression 
of the introduced transgenes. We used immunofluorescence, X-Gal staining and a luciferase 
assay. The results showed nicely that luciferase is highly expressed in the transgenic miPS 
clone 5 cells compared to non-transgenic miPS cells (Fig. 5 and 6). Intensive staining for β-
Galactosidase in miPS clone 5 cells confirmed these results (Fig. 5). 
The characterization confirmed that miPS clone 5 cells show pluripotent characteristics and 
express the introduced transgenes in equal amounts compared to mES cells. 
 
Fig. 1 
Real-Time RT-PCR for detection of core pluripotency markers, normalized against TATA Box Binding Protein 
(Tbp) as reference gene. Error bars correspond to the standard error of the mean (S.E.M.). Data were generated 
from duplicates of three independent experiments. One star represents p<0.05, two stars represent p<0.01, three 
stars represent p< 0.001. 
Except for Nr5a2 and Tbx3, no significant differences in expression between mES and miPS clone 5 cells were 
detected. In mEF cells only Klf4 and Tbx3 were expressed at detectable levels but significantly lower compared 





Real-Time RT-PCR for detection of naive pluripotency markers, normalized against Tbp as reference gene. 
Error bars correspond to the S.E.M. Data were generated from duplicates of three independent experiments. One 
star represents p<0.05, two stars represent p<0.01, three stars represent p< 0.001. 
The majority of naïve pluripotency markers were expressed evenly in mES and miPS clone 5 cells. Expression 
of Dax1, Dazl and Stra8 differed between mES and miPS clone 5 cells. Expression of Dazl was almost doubled 
in mES cells compared to miPS clone 5 cells. Dax1 expression was significantly higher in miPS clone 5 cells 
compared to mES cells. For Rex1 the p-value was close to a one star significance with a p-value of 0.054. Stra 8 
expression was found to be over two times higher in mES cells compared to miPS cells. mEF cells did only 





(A) Western blot analysis of core pluripotency markers, normalized against ɑ-tubilin as reference gene. Error 
bars correspond to the S.E.M.. Samples were analyzed in triplicates. One star represents p<0.05, two stars 
represent p<0.01, three stars represent p<0.001. 
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In contrast to the similar expression of Nanog in mES and miPS clone 5 cells, Oct4 and Sox2 show significant 
differences between the three groups. Expression in mEF is 10-20-fold lower in comparison to mES or miPS 
clone 5 cells. Oct4 and Sox2 expression is significantly higher in miPS clone 5 cells compared to mES cells, 
with an approximate 1.5 fold difference.  
(B) Scan of Western blots after development of the film in a darkroom. Each well was loaded with 10mg protein 
solution. Each cell line was blotted in triplicates on the same gel. The band of mES-2 was taken as reference 
band between blots. 
 
Fig. 4 
Immunofluorescence images. All images were taken with a 63x oil UV objective. 
Green = epitope, blue = DAPI, scale bars = 50µm 
Images of mES, miPS clone 5 and mEF cells showed expression of core pluripotency markers in both mES and 
miPS clone 5 cells, but not in mEF. mES cells show a more uniform, but weaker signal distribution of Nanog 
compared to miPS clone 5 cells. In clone 5 the weak signal is in some cases linked to cells during the metaphase 
(arrows) but independent of the state of the chromatin density as well (arrowheads). The naïve pluripotency 
marker SSEA1 signal is stronger as well in clone 5 compared to mES cells. The TRA98 stain shows an irregular 
pattern between high and low-level expression areas in both mES and clone 5. Low signal areas (stars) are 
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independent of the state of chromatin as well as the cells with high signal for TRA98. mEF cells showed no sign 
of the stained markers expect for unspecific background staining for Sox2. 
 
Fig. 5 
Confocal immunofluorescence images of luciferase and DAPI images taken with a 20x air objective. Green = 
epitope, blue = DAPI, Scale bar =50µm 
X-Gal staining pictures were taken with a phase-contrast microscope with a 10x air objective. Blue = X-Gal, 
Scale bar = 50 µm 
The native miPS cells showed only a weak background staining (circle). miPS clone 5 cells showed a high signal 
of luciferase. The blue colonies indicate a high activity of β-Galactosidase in miPS clone 5 cells. Native miPS 
cells did not show β-Galactosidase activity. 
 
Fig. 6 
Luciferase assay of miPS and miPS clone 5 cells. All samples were analyzed in triplicates. This analysis showed 
a massive signal of luciferase in miPS clone 5 cells compared to miPS cells. In miPS cells the signal was near to 




4.2 miPS clone 5 cells show sex-chromosome alterations 
Another goal for this study was to identify the cells after they were injected into the mice. To 
have an additional marker we targeted Y-Chromosome-specific genes. The miPS cells were 
XY-karyotype male cells and the mice were XX-karyotype females. Since the injected cells 
originated from male mice and the mice for the teratoma assay were female, a clear 
distinction between mouse cells and injected transgenic cells should have been possible. We 
have chosen Sry and Zfy which represent Y-Chromosome-specific genes in mice and Xist as 
an X-Chromosome-specific gene. 
Preliminary real-time PCR results were not able to detect Sry or Zfy in miPS clone 5 cells. 
We therefore extended the analysis to more cell lines, to rule out eventual technical errors. 
The analysis of five cell lines revealed that the transgenic cell lines mES clone 11, miPS 
Luc/Lac and miPS clone 5 showed a signal for the transgenes luciferase and LacZ but not for 
Sry and Zfy (Fig. 7). In the original cells that were purchased (mES, miPS, miPS Luc/Lac), 
Zfy and Sry were detectable. 
For further investigation of the chromosome set we decided to conduct fluorescent in-situ 
hybridization (FISH) analysis of the whole chromosome set of miPS, mES and miPS clone 5 
cells. The analysis confirmed the previous PCR results. While the original miPS and mES 
cells showed a signal for the Y-Chromosome, the miPS clone 5 cells did not show a signal 
(Fig. 8A). In miPS clone 5 only a small band appeared inside the telomere region of the X-
Chromosome. A karyogram of the miPS clone 5 cells showed that there are no further 
chromosome set alterations in terms of polyploidity or lack of another chromosome (Fig. 8B). 
These results have a high impact on this study, since chromosome alterations would prohibit 
the application of cells in clinical trials for fertility restoration. Furthermore the question was 
raised if male cells without Y-Chromosome can give rise to healthy and fully functional male 
germ cells in vivo. The results also implicated a more elaborate and thoroughly screening of 





Real-time PCR of DNA of mES and miPS cells. Erros bars correspond to the S.E.M. Data were generated from 
duplicates of three independent experiments. All cells originate from XY-karyotype murine cells. One star 
represents p<0.05, two stars represent p< 0.01, three stars represent p<0.001. miPS clone 5 is a single cell- 
derived cell clone of miPS Luc/Lac cells. 
Xist is detectable in all five cell lines. mES cells showed a significant higher signal compared to the other cell 
lines for Xist, Zfy and Sry. Signals for Sry and Zfy were not detectable in miPS clone 5 and mES clone 11, but 
in mES, miPS and miPS Luc/Lac cells respectively. The signal of luciferase was significantly higher in miPS 
Luc/Lac cells than compared to miPS clones 5 and mES clone 11. Differences between the miPS clone 5 and 
mES clone 11 showed low significance. mES clone 11 showed the highest signal for LacZ compared to the 





(A) FISH painting of Chromosomes. Pink = gonosomal X-Chromosome, blue= Y-Chromosome 
(B) Complete karyogram of miPS clone 5 cells 
FISH painting and karyogram of miPS clone 5 cells revealed that miPS and mES cells have very well visible sex 
chromosomes (pink staining, double arrow = X-Chromosome and blue staining, arrow = Y-Chromosome). miPS 
clone 5 cells showed a small band inside the arms of the sex-Chromosome (pink staining, arrowhead). The band 
appears in the distal region of the X-Chromosome (arrowhead) and the X-Chromosome seems elongated. The 
chromosome analysis confirmed the absence of a Y-chromosome. 
4.3 An extended unstimulated time period of GoST cells reveals a new cell phenotype 
One of the major questions addressed by this study was if GoST induction can be conducted 
with miPS cells in changed culturing methods by addition of 2iL to the medium. 
miPS clone 5 cells were cultured for 10 passages in 2iL + βME plus Ex527 and RG108. The 
resulting cells were described as cmiPS clone 5 cells. WT cells were cultured in 2iL + βME + 
DMSO. cmiPS clone 5 cells were deprived of 2iL and tBHQ was added for seven days. WT 
cells were deprived of 2iL as well and were cultured in BM with DMSO. After seven days the 
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cmiPS clone 5 cells showed the morphology of GoST cells1 and appeared vital (Fig.9). The 
resulting cells were described as GoST cells. Flat cells grew to 100% confluence between the 
former colonies (Fig. 9). In WT cells the colonies appeared as dark spots and small round 
cells were floating between the colonies (Fig. 9). 
 
After this preliminary experiment we conducted the GoST induction on cmiPS clone 5 cells 
and compared the macroscopic appearance and mRNA expression patterns of pluripotency, 
germ cell and spermatogonial stem cell (SSC) markers to WT treated cells. After GoST 
induction of cmiPS clone 5 cells we observed both groups for an unstimulated time period of 
20 days in BM plus DMSO. For WT cells the observed time points were taken before the 
unstimulated time period (D0) and in four-day intervals (D0+4, D0+8, D0+12, D0+16, 
D0+20). For cmiPS clone 5 and GoST cells the observed time points were after 10 passages 
in conditioning medium, right before GoST induction (D0), right after GoST induction (D7) 
and then in four-day intervals (D7+4, D7+8, D7+12, D7+16, D7+20). The cells after D7 were 
described as GoST cells. 
Light microscopy images show that the morphology of the cells does differ in terms of cell-
layer thickness and height of the former colonies until 12 days without stimulation (Fig. 10) 
between WT and GoST cells. WT cells did show a thicker cell layer between the colonies 
whereas GoST cells appeared to have only a thin layer of cells. Both groups showed black 
spots were the former cell colonies were. After this point WT cells did not show a significant 
change to their morphology (Fig. 10). After 16 days without stimulation GoST cells spawned 
small round cells around and on top of former colonies that were multiplying until D7+20 and 
filled the dish (Fig. 10). 
This unexpected observation raised the question if the round cells resemble a known cell type. 
Since the GoST induction induces germ cell markers we suspected the round cells to be germ 
cell- or SSC-like cells. 
For further investigation of the GoST and round cells, real-time RT-PCR of mRNA from 
GoST and WT cells was conducted. 
At first, we investigated core and naïve pluripotency markers throughout the observed time 
points. Especially with regard to the previous observation of the round cells we were curious 




Most of the core pluripotency markers were significantly downregulated during the 
unstimulated time period (Fig. 11). Only Klf4 and Tbx3 were still expressed after release of 
2iL. In GoST cells the expression of Klf4 showed a high increase after D7. WT cells did 
express Klf4 as well, but in lower fashion compared to GoST cells. Both groups showed initial 
downregulation of Klf4 expression, but then showed upregulation (Fig. 11). In WT cells the 
expression of Klf4 peaks at D0+12 and decays afterwards (Fig. 11). GoST cells show a high 
increase of Klf4 expression from D7 until D7+20 with significantly higher expression 
compared to WT cells (Fig. 11). The Tbx3 expression showed no significant differences 
between the two groups in the observed time points (Fig. 11). Expression of Tbx3 in WT cells 
peaks at D0+12 and then decreases until D0+20 (Fig. 11). Tbx3 expression in GoST cells 
peaks at D7+4 and D7+8 and then decreases (Fig.11). In previous work using mES cells1, it 
was shown that GoST cells maintain expression of core pluripotency markers at similar levels 
compared to untreated cells at D0. Contrary to this previous work1, the expression of all core 
pluripotency markers (Nanog, Oct4, Sox2, Nr5a2, Esrrb, Klf4, Tbx3) was downregulated in 
GoST cells (D7) compared to WT cells (D0). This observation implies that miPS clone 5 cells 
in the current study did not react in the same way to GoST induction as mES cells in previous 
work1. 
 
Analysis of naïve pluripotency markers showed downregulation in both groups throughout the 
unstimulated time period. 
Dax1, Dppa3 and Prdm14 were highly downregulated after 20 days of unstimulated culturing 
(Fig. 12). Fbxo15 was highly downregulated after 20 days too, but increased shortly at D0+12 
in WT and D7+20 in GoST cells (Fig. 12). Prdm14 showed similar expression patterns in WT 
and GoST cell. Expression levels of Piwil2, Rex1 and Stra8 stand out in this analysis. Piwil2 
expression increased in both groups between 4 and 12 days in unstimulated culture conditions 
(Fig. 12). Rex1 shows a plateau phase after an initial decrease of expression at D0. After 12 
days of unstimulated culture conditions the expression decreases slightly in the next observed 
time points. Stra8 shows low levels of expression in both groups initially. In WT cells Stra8 
expression increases after 8 days in unstimulated culture conditions with a peak at D0+12. 
Afterwards the expression is heavily downregulated to levels equal to D0. In GoST cells Stra8 
expression levels show a high increase after 4 days of unstimulated culture and peaks at D7+8 
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(Fig.12). Afterwards Stra8 expression is massively downregulated to near to non-detectable 
levels at D7+20 (Fig. 12). 
The analysis of core and naïve pluripotency markers revealed that both WT and GoST cells 
are no longer pluripotent since most of the markers were downregulated during the 
unstimulated time period (Fig. 11 and 12). This indicates that WT and GoST cells have 
differentiated. Most of the expression patterns throughout the observed time series did not 
differ between WT and GoST cells. Since GoST induction induces germ cell-like features in 
mES cells, our next step was the investigation of germ- and spermatogonial stem cell-specific 
markers on mRNA levels. 
The analysis of germ cell markers showed that most of the markers were detectable in both 
groups at some points of the observed time points (Fig. 13). An interesting observation was 
that some markers showed similar expression patterns in both groups. Ddx4 shows an increase 
of expression until 12 days in unstimulated culture conditions and then gets downregulated 
until 20 days (Fig. 13). Nanos2 is expressed at low levels in the first two time points and then 
gets highly upregulated after 8 and 12 days (Fig. 13). At 16 and 20 days, Nanos2 gets 
downregulated to basal levels. Dazl expression is upregulated in both groups as well, but the 
peak is shifted. In WT cell the peak expression of Dazl is detected at D0+12 and then 
expression decreases massively. In GoST cells the peak expression of Dazl can be detected 
after 8 days in unstimulated culture conditions and then decreases massively. WT cells did 
also show a plateau phase of Dazl expression from D0 to D0+8. Zbtb16 expression peaks at 
the same time points as Dazl in both groups and then the expression decreases. A prominent 
difference between both groups was the very low expression of Zbtb16 in WT cells at D0 and 
D0+4 compared to D7 and D7+4 in GoST cells. Tdrd1, Plk1s1 and Tex101 showed 
upregulation throughout the observed time points in both groups. Tex101 is highly 
upregulated in WT cells from D0+4 until D0+12 and then downregulated to a plateau level at 
D0+16 and D0+20. GoST cells show a peak in Tex101 expression at D7+4 and then 
expression is downregulated to levels of D7 at time points D7+16 and D7+20. Plk1s1 
expression peaks around 12 days in unstimulated culture conditions in both groups. The 
overall expression of Plk1s1 is higher in GoST cells compared to WT cells and peaks in both 
groups after 12 days in unstimulated culture conditions. Expression of Tdrd1 decreases in 
both groups at 4 (GoST cells) and 8 days (WT cells) in unstimulated culture conditions. The 
peak expression of Tdrd1 is at D0+16 in WT cells and D7+8 in GoST cells. After the peak, 
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Tdrd1 is downregulated in both groups. The overall expression of Tdrd1 is higher in WT cells 
compared to GoST cells. 
Analysis of germ cell markers showed that in both groups deprivation of inhibiting factors 
induces germ cell-specific markers. Based on our observations the most important period of 
time seems to be around 8 to 12 days after release from 2iL. Especially the similarities in 
expression patterns throughout the observed time points stand out compared to the core and 
naïve pluripotency markers. The round cells appeared 16 days after release from 2iL while 
most of the germ cell markers are downregulated after this time point. Thus a clear correlation 
between the analyzed germ cell markers and the appearance of the round cells could not be 
found. 
Due to the morphology of the round cells which, showed similarities to SSCs, we investigated 
SSC-specific markers as well. While most of the SSC markers are not expressed at D0/D7 in 
both groups, the markers were upregulated during the observed time period (Fig. 14). CD53, 
Csf1r and Ifi203 were not or extremely low expressed in both groups at D0/D7. All three 
markers showed upregulation after the release of 2iL. Upregulation of CD53 only appeared at 
D0+16 and D0+20 in WT cells. In GoST cells CD53 was upregulated 8 days after release and 
peaked at D7+12. Then the signal decayed until D7+20 in GoST cells. The expression of 
CD53 was significantly higher in GoST cells compared to WT cells. Csf1r showed similar 
expression patterns, although the expression started earlier in both groups (Fig.14). In WT 
cells Csf1r expression started 4 days after release of 2iL and continuously increased over 
time. GoST cells already expressed Csf1r at very low levels before release at D7. The 
expression peaks at D7+16 and then decreases in GoST cells. The overall expression of Csf1r 
is significantly higher in GoST cells than in WT cells. Exactly the same expression pattern 
was observed for Ifi203, with a constant increase of expression in WT from D0+8 on and a 
peak expression at D7+16 in GoST cells (Fig.14). Col1a2 and Gfra1 did not show such a 
regular expression pattern in both groups compared to the other markers. Col1a2 showed 
upregulation on WT cells from D0 until D0+8. Then the signal decreases until D0+16 and 
increases again at D0+20. In GoST cells the expression of Col1a2 showed a steady decrease 
from D7 until D7+12. Then the Col1a2 gets upregulated at D7+16 and downregulated at 
D7+20. Gfra1 showed a peak expression in WT cells at D0+4 and then decreases until 
D0+20. GoST cells showed a steady upregulation of Gfra1 throughout the observed 20 days. 
The peak at D7+20 was significantly higher compared to the peak at D0+4 of WT cells. 
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The results of SSC markers showed upregulation of the tested markers in both groups. The 
peak expression points were generally higher in GoST cells except for Col1a2. A striking 
result is that SSC markers were expressed in both groups. This result was unexpected, since 
usually PS cells tend to differentiate into neuroectodermal cells when released of inhibiting 
factors. The only SSC marker that shows upregulation in correlation with the appearance of 
the round cells is Gfra1 with a peak expression at D7+20 in GoST cells and low levels of 
expression in WT cells. We therefore expected that Gfra1 upregulation is a result of the 
growing round cell population, since they only appeared in the GoST cell group. Nevertheless 
the 16-day mark after release of 2iL seems to be an important time point in terms of SSC 
marker expression, since in both groups the expression of most of the markers either increased 
or decreased massively. 
Since Gfra1 seemed to be the only marker of which the expression fits the appearance of the 
round cells we decided to conduct confocal immunofluorescence images with anti-Gfra1 
antibodies (Fig. 15). As we assumed that the round cells resemble SSC-like cells, we 
additionally stained for the germ cell-specific marker TRA98 (Fig. 15 and 16). 
The confocal images showed that the expression of TRA98 is not only found in GoST cells, 
but in WT cells as well (Fig. 15 and 16). The round cells showed a weak signal for TRA98 at 
D7+16 and D7+20 while WT cells showed a more intense staining compared to the round 
cells throughout the observed time points (Fig. 15 and 16). Gfra1 showed unspecific 
background staining and no correlation between signal and round cells in GoST cells or WT 
cells (Fig.15). 
The confocal images showed no clear evidence of SSC-like cellular features of the round 
cells. Since TRA98 and Gfra1 showed no distinct difference between the two groups, the 
question which kind of cells the round cells represent remained unclear. 
Overall the characterization of the GoST induction series revealed that GoST and WT cells 







Phase-contrast microscopy of miPS clone 5 cells with and without GoST induction after seven days. Images 
were taken with a 10x air objective. Scale bar = 100 µm 
These images show the effect of the GoST induction in comparison to exposure to BM and DMSO. WT and 
cmiPS clone 5 cells look vital and similar in shape and thickness of the colonies at D0. In GoST cells, after seven 
days of release from 2iL plus βME, the area between the former colonies is filled with flat cells. In WT cells the 
space between the former colonies is filled with cellular debris. Cells in the WT–treatment did float around and 
could be washed away easily; therefore this sample was not mounted with a coverslip. Furthermore, WT cells 
appear to be dead and are scattered around the former colonies at D7. GoST cells appeared vital and were able to 
fill the gaps between the colonies with flat cells. GoST cells were sticking tightly to the surface of the culture 







Phase contrast microscopy of WT and GoST cells after release of 2iL medium. Images were taken with a 10x air 
objective. Scale bar =50 µm 
The comparison of WT and GoST cells from D0 or D7 on respectively until 20 days without stimulation 
revealed differences in cell morpholgy. Differences lie in the thickness of the cell layer between the colonies. 
Initially there are no cells between colonies in both groups. The colonies undergo a change in appearance from 
translucent at D0 to dark and opaque during the series (arrows). This effect appears earlier in GoST cells (D7) 
compared to WT cells (+12). For GoST cells, this effect decreases after +12. At time point D0+4 for WT and D7 
for GoST cells, a thin layer of cells (circle for WT cells, square for GoST cells) grew between the colonies 
(arrows). While the WT cells develop a thick cell layer from timepoint +8 on, the GoST cells have a thin cell 
layer in this region until +16. The layer in WT cells does not change significantly after time point +12, whereas 
in GoST cells small round cells appear in the periphery of former cell colonies (star). Those cells appeared in 
higher amounts at time point +20, predominating the field of view in the culture dish and overgrew the 
underlying flat cell-layer at this point. The round cells could be found floating in the culture medium. Round 
cells did not appear in WT cells at any observed time point. 
 
Fig. 11 
Real-time RT-PCR of mRNA for core pluripotency markers of the GoST series, normalized against Glycerine-3-
Phosphate-Dehydrogenase (Gapdh). Data were generated from duplicates of three independent experiments. The 
error bars correspond to the S.E.M. One star represents p<0.05, two stars represent p<0.01, three stars represent 
p<0.001. 
The investigation of the mRNA expression of core pluripotency markers during GoST induction or WT-
treatment showed an overal downregulation except for Klf4. Klf4 showed upregulation in GoST cells. First, 
41 
 
there is a highly significant decrease in expression in both groups, but over time Klf4 is higly upregulated in 
GoST cells until timepoint D7+20. In WT-cells the increase peaks at timepoint D0+12 and then decreases. The 
expression of Klf4 at timepoint D7+4 and D7+20 is significantly higher in GoST cells compared to WT cells. 
Expression of Nanog, Sox2, Oct4 and Esrrb decreases over the observed time points to near to non-detectable 
levels. The Tbx3 expression throughout the unstimulated time period showed a significant increase in the WT 
cells from timepoint D0+4 to D0+12, then the signal decreased again near to non detecable levels. In GoST cells 
no significant change from D7 on was observed despite the initial decrease in expression for Tbx3. 
 
Fig. 12 
Real-time RT-PCR of mRNA for naïve pluripotency markers of the GoST series, normalized against Gapdh. 
Data were generated from duplicates of three independent experiments. The error bars correspond to the SEM. 
One star represents p<0.05, two stars represent p<0.01, three stars represent p<0.001. 
The analysis of naïve pluripotency markers of the GoST series revealed that all markers except for Piwil2 and 
Rex1 decreased over time. Dax1, Dppa3, Fbxo15 and Prdm14 show significant downregulation over the 20 days 
of unstimulated culture. Dppa3 showed a plateau phase from D0 until D0+12 and then decreased expression until 
D0+20 in WT cells. In GoST cells a highly significant and steady decrease of Dppa3 from D7 until D7+20 
appears. Fbxo15 expression increases at time point D0+12 after a plateau phase until time point D0+8, but then 
decreases in the last two time points. Rex 1 shows a highly significant initial decrease and plateaus throughout 
the whole unstimulated time period in both groups. Expression levels of Stra8 showed in both groups a high 
increase until D0+12 or D7+8 respectively, while both peaks differ significantly in signal. After this the peak of 
Stra8 expression decreases until the last observed time point. Piwil2 shows the same pattern of increasing signal 
in WT and GoST cells. Piwil2 expression increases until 12 days under unstimulated culture and then decreases 





Real-time RT-PCR of mRNA for germ cell markers of the GoST series, normalized against Gapdh. Data were 
generated from duplicates of three independent experiments. The error bars correspond to the SEM. One star 
represents p<0.05, two stars represent p<0.01, three stars represent p<0.001. 
Analysis of mRNA expression levels shows a highly significant decrease of Dazl expression after an increase in 
WT cells until day 16 under unstimulated culture conditions. In GoST cells the Dazl expression increases at 
D7+4 until D7+8, but decreases as well from time point D7+16 on. The expression patterns in WT and GoST for 
Ddx4 show similarities. In WT cells the increase of expression is significantly higher than in GoST cells 
although expression at D7 in GoST cells is already significantly higher than in WT cells. Although the peak is 
not significantly higher than the start and the end points, an increase of signal at the D7+12 is detectable which 
decreases off until D7+20, just like in WT cells. The expression of Nanos2 only shows high expression at time 
points +8 and +12 in WT and GoST cells while GoST cells showed a higher expression but with a very high 
SEM value. Plk1s1 and Zbtb16 show similar patterns in the two groups. First, there is an increase of expression 
until 12 days in unstimulated culture conditions. Afterwards a significant decrease to almost starting levels is 
present in both WT and GoST cells. The overall expression of Plk1s1 and Zbtb16 is higher in GoST cells 
compared to WT cells. The expression of Tdrd1 is higher in WT cells throughout the series compared to GoST 
cells, although the first time points are significantly higher in GoST cells. After the increase of expression af 
Tdrd1 until 12 or 16 days in unstimulated culture conditions the expression decreases to starting levels. For 
Tex101 the peak expression is significantly higher in WT cells than in GoST cells, but decreases after time point 
+12. In GoST cells the expression levels to the D7 time point, while in WT cells the increase of expression 20 





Real-time RT-PCR of mRNA for spermatogonial stem cell markers of the GoST series, normalized against 
Gapdh. Data were generated from duplicates of three independent experiments. All samples were analyzed in 
triplicates. The error bars correspond to the S.E.M. One star represents p<0.05, two stars represent p<0.01, three 
stars represent p<0.001. 
At first, some spermatogonial stem cell markers were not expressed in both groups, but showed significant 
differences throughout the series. In Cd53 the expression started in WT cells at D0+16, but did not increase 
significantly at D0+20. In GoST cells the expression starts at time point +8, peaks at +12 and decreases until 20 
days after release of 2iL. The expression of Cd53 is significantly higher in GoST cells compared to WT cells 
until 16 days after release of 2iL. The Csf1r expression shows a highly significant increase in both WT and 
GoST cells. In GoST cells Csf1r expression is higher compared to WT cells and decreases after the peak at time 
point +16. This peak shows a high significance towards the other time points with an approximate 2 fold higher 
expression. The expression of Gfra1 shows a great difference between the two groups. In WT cells the 
expression increases from timepoint D0 to D0+4, but decreases afterwards and stays at this level throughout the 
remaining time points. In GoST cells Gfra1 expression increases steadily throughout the series, but also shows 
significantly higher levels of expression at its peak at +20 compared to WT cells at time point D0+4. Althought 
the level of expression in GoST cells does not increase significantly until D7+16, at D7+20 the expression is 
massively increased.The expression of Ifi203 starts earlier in GoST cells and peaks at time point D7+16, while in 
WT cells the expression is delayed to D0+12 and peaks at D0+20. The peak expression of Ifi203 is significantly 
higher in the GoST cells compared to WT cells. 20 days after release of 2iL the expression of Ifi203 does not 







Immunofluorescence images of the GoST series. All images were taken with a 63x oil UV objective. 
Greyscale = TRA98, Green = Gfra1, Blue = DAPI, Scale bars = 50µm 
These images show the expression of the nuclear marker TRA98 and the surface marker Gfra1. At D0 the 
TRA98 stain shows the previously observed heterogeneous pattern in both WT and GoST cells, before the start 
of the chemical treatment. While the TRA98 signal decreases in WT cells over the observed time points, the 
GoST cells still show positive cells until 20 days after release of 2iL. The image at D7+20 in GoST cells shows a 
cell cluster of round cells. These cells still have a TRA98 signal, although it is weaker than in colonies at D7+16. 
The Gfra1 signal in general shows heterogeneous staining patterns. This signal is weak to non-detectable in WT 
cells over the 20 days. The only signals are detectable at D0+16 and D0+20 in a few areas. In GoST cells the 
signal increases from D7+4 on and seems to be correlated to TRA98-negative cells. At time point D7+20 the 
Gfra1 positive regions are beneath the TRA98 positive round cells. However the Gfra1 signals does not correlate 
with the DAPI stain very well. For a cell-surface marker it would be expected to get a similar staining as in 
SSEA1 (Fig. 4). The DAPI signal shows a high amount of nuclear fragments in the beginning of the 
unstimulated time period of both WT and GoST cells. These fragments disappear in the course of the 
unstimulated time period. The nuclei show a high variance in size and shape throughout the series. This does not 





Immunofluorescence images of the GoST series. All images were taken with a 63x oil UV objective. 
Greyscale = TRA98, Blue = DAPI, Scale bars = 50µm 
The confocal images of TRA98 antibodies showed that TRA98 is expressed in WT and GoST cells during the 20 
days of unstimulated culture. The signal in WT cells is brighter compared to the round cells of D7+16 and 
D7+20. The round cells expressed TRA98 in irregular patterns throughout the round cell population. mEF cells 




4.4 GoST cells show reduced tumor growth, but still contribute to teratoma formation 
The measurements of the tumor diameters revealed that in the lowest cell dose no differences 
between the two groups are visible (Fig. 17). In the 104 cell dosage WT cells proliferated in 
all 5 mice almost uniform and all mice reached the end point at the same time (Fig. 17). In the 
GoST cell group only two mice reached the end point at the same time as the WT cell injected 
mice. The remaining mice in this group developed slow growing tumors. Two mice of the 
GoST cell group reached the end point of the study after 91 days. In the highest cell dosage of 
3*106 cells the WT cells proliferated faster and 4 out of 5 mice reached the end point around 
27 days of the study (Fig. 17). At the highest cell dosage in GoST cell injected mice the 
tumors did grew slower than in the WT group and one mouse reached the end point of the 
study after 91 days (Fig. 17). The analysis of the average survival time (AST) showed that 
mice that were injected with GoST cells in the two highest cell dosages reached the end point 
later than mice that were injected with WT cells (Fig.17). 
Although GoST cells still contributed to tumor formation, the GoST cell-derived tumors 
proliferated slower on average compared to WT cells. This effect was positively correlated 
with higher cell dosage in WT cells. The reasons why GoST cells proliferated slower 
compared to WT cells and what kind of tumor GoST cell contribute to could not be assessed 
by this experiment. Therefore we conducted an in vivo imaging (IVIS) for luciferase with a 
follow-up necropsy and histological analysis of each mouse. 
The IVIS confirmed that all tumors originated from the injected cells (Fig. 18). The signal of 
each tumor correlated very well with the measured size and position of the tumors (Fig.18). 
We concluded that there was no spontaneous tumor growth and that the injected cells 
survived throughout the teratoma assay since they could still metabolize the injected D-
Luciferin. 
The histological analysis revealed two types of tumors in both groups. The first type of 
tumors is the so called “florid” tumor. Florid tumors represent the fast-growing tumors in both 
groups and consisted of cells derived from the three germ layers, ectoderm (Fig. 19 Ai and 
Bi), mesoderm (Fig. 19 Aii and Bii) and endoderm (Fig. 19 Aiii and Biii). Therefore florid 
tumors can be classified as teratoma. Florid teratomas showed signs of vascularization (Fig. 
19. A and B). The second type of tumor is the so called “atrophic” tumor. Atrophic tumors 
represent the slow or not growing tumors in both groups. Atrophic tumors were only found in 
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the lowest cell dosage of injected WT cells. The atrophic tumors consisted of cells derived 
from the three germ layers, ectoderm (Fig. 20 Ci and Di), mesoderm (Fig. 20 Cii and Dii) and 
endoderm (Fig. 20 Ciii and Diii). Therefore atrophic tumors can be classified as teratomas as 
well. Atrophic teratomas showed signs of degenerated nuclei and dead cells (Fig. 20 C and 
D). Furthermore they showed no signs of vascularization (Fig. 20 C and D). Both tumor types 
showed differences in the intensity of H&E staining between both groups. WT tumors tend to 
be paler than GoST cell tumors (Fig. 19 A and B, Fig 20 C and D). The H&E staining 
revealed that WT and GoST cell teratomas showed no sign of invasion or damaging of the 
surrounding tissue (Fig. 19 and 20). 
The results of the teratoma assay showed that GoST induction does not prevent teratoma 
formation. However the tumor growth of GoST cells was reduced and the mice remained on 
average longer in the study compared to WT cells. We therefore concluded that the GoST 
induction effects the tumor growth potential. This effect is ambiguous though. As we 
observed downregulation of core pluripotency markers in GoST cells (D7), it is also possible, 
that the reduced tumor growth was caused by reduced pluripotency due to the removal of LIF 





Diameters of the tumors were measured manually using a sliding caliper once a week. The total study lasted 13 
weeks (91 days). Each group consisted of 5 mice. End-point for the mice were tumor diameters >15 mm or a 
score >12 according to the score sheet (S5). AST = Average survival time. 
Throughout the teratoma formation study differences in growth behavior between injected WT and GoST cells 
appeared. For the lowest cell dosage of 100 injected cells the growth curves look quite similar between WT and 
GoST cells with two mice reaching the end point of the animal experiment in each group at the same time (day 
34 and day 79) and three mice staying in the experiment the full 13 weeks (91 days) with a steady tumor 
diameter around 3-6mm. The AST are equal in this cell dosage (71.4d). The curves are meandering around this 
value in the GoST cell group, but not in the WT group. In the 104 cell dosage differences between the two groups 
appeared. In the WT cells all mice reached the end point around the same time (day 30-34). In GoST cells only 
two mice reached the end point at day 30, but the remaining mice stayed longer in the experiment. It was 
observed that the diameter of the tumor of mouse #9 and #8 decreased after a peak around day 30. Only one 
mouse in the GoST cell group reached the end point after day 30 around day 79. Most of the GoST cell-derived 
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tumors did grow slowly. Measureable tumor growth e.g. in mouse #2 started at day 34 and had a slow growing 
curve, while in the WT cells tumors grew rapidly and the last mouse was sacrificed at day 34. The remaining 
mice in the GoST cell group had a similar tumor diameter of approximately 3mm, which did not increase over 
time. The AST was higher in the GoST cell group with 59.2 days compared to 40.4 days in the WT cell group. 
The highest injected cell dose of 3 million cells showed a similar result as the 104 cell dose in the WT group. The 
end point for 4 mice in the WT group was reached at around day 27 and the last mouse was sacrificed at day 30. 
In the GoST cell group, three mice reached the end point around day 27. One mouse reached the end point at day 
62 and the last mouse stayed in the experiment for the full duration of 13 weeks. For mouse #11 the curve 




IVIS images of mice 5-10 minutes after injection with D-Luciferin. The Signal is based on emitted photons and 
displayed by a color gradient from red (= high signal) to blue (=low signal). 
The images show that every tumor originated from the luciferase positive cells that were injected. Size and 
region of the tumors correlate well with the measured diameter (Fig. 17) and the injection site. Although the 
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signal is very weak in mouse #1 and #8 there is still some signal detectable. Most of the mice show one hot spot 
with a high signal in the center and fading signal towards the periphery. Some mice like #11, #14 and #16 show 
several high signals in one hot spot with fading signals from the center to the outside. Mouse #26 and #27 show 
two separate hot spots which show one high signal in the center each with fading signal towards the periphery. 








H&E staining of paraffin embedded tumor sections. Images were taken from florid tumors representatively for 
other tumors of the same quality and morphology. Scale bar = 10mm 
Fig. 19A panel represents the overview of a florid WT cell-tumor. The tumor only grew under the skin and did 
not infiltrate the surrounding tissue. Different parts of the tumor show variable intensities of staining. Image Ai 
shows an area of neuroectodermal tissue, which shows signs of primitive neurons and glia cells. Image Aii 
shows a piece of cartilage, which represents differentiated mesodermal cells. In Aiii dilated glandular tissue with 
cells inside and ciliated epithelium is visible. Image B represents the florid GoST cell tumors. Fig. 19B 
represents a florid tumor derived from GoST cells. The tumor did not infiltrate the surrounding tissue and was 
separated from the skin, which is visible at the edge of the image. The staining is more intense as in the WT 
tumor. In Bi an area of primitive neuroectodermal tissue is visible. Bii shows pieces of cartilage and pieces of 
bone inside the tumor, which both derived from the mesoderm. The endodermal offspring is shown in Biii with 
dilated glandular structures that contain clumps, which represent in this case neuroectodermal cells, and is 
equipped with ciliated epithelium on the inner cellular layer. The images show no difference in the constituent 
parts of the tumors that grew over 15 mm in diameter. Since the tumors did include tissue from all three germ-








H&E staining of paraffin embedded atrophic tumor sections. Images were taken from atrophic tumors 
representatively for other atrophic tumors with the same quality and morphology. Scale bar = 2.5mm 
Panel C represents the overview of an atrophic WT tumor. The tumor did not infiltrate its surrounding tissue and 
grew in the subcutaneous space. The staining shows similar intensity to the skin. In Ci nervous tissue, which 
represents the ectoderm, crossed by a glandular structure is shown. The cells lie in a high amount of matrix, 
which fills the space between the nuclei. In Cii skeletal muscle cells are visible, which originated from the 
mesoderm. Ciii shows a part of the tumor with several highly dilated glandular structures equipped with ciliated 
epithelium, which includes cells and fluids. Panel D shows the overview of a GoST cell-derived tumor. Intensity 
of the staining is higher than the surrounding tissue. The tumor is attached to the external layer of the abdominal 
muscle, but did not infiltrate the surrounding tissue. Image Di shows primitive neuroectodermal tissue. Dii 
shows a piece of cartilage, derived of mesodermal stem cells. The endodermal derivative is represented by a 
small glandular structure that lies in primitive neuroectodermal tissue. This gland is equipped with ciliated 
epithelium and contains cells and fluid that stained with H&E. Since both the WT- and GoST-derived tumors did 
contain cells from all three germ layers, these tumors can be classified as teratoma, similar to the florid tumors. 
The most significant differences between atrophic and florid tumors are the atrophic features and the lack of 
vascularization in atrophic tumors.  
4.5 Injected cells showed signs of cellular migration 
Since the teratoma assay showed promising results concerning the growth of tumors derived 
from GoST cells, we wanted to investigate a possible migration of stem cells from the 
injection site into the body of the mice. Since the injected cells were transgenic for β-
galactosidase and luciferase, we isolated DNA from organs with subsequent PCR for 
luciferase to detect migrated transgenic cells. We have chosen typical bottlenecks in the body 
for migrating cells like liver, spleen and lung. For negative control of the transgenes we 
isolated DNA from earpunches of each mouse prior to injection. For detection of the injected 
cells we have chosen luciferase, since it was highly expressed in the injected cells (Fig. 21). 
As marker for DNA we have chosen Xist, an X-Chromosome silencing gene that is expressed 
in every cell independent of gender. This control was necessary since we expected no signal 
for luciferase in the organs. The initial plan to use a Y-Chromosome-specific gene as a second 
detection marker for the injected cells failed, since the injected cell did not have a Y-
Chromosome (Fig.8). 
In a preliminary experiment we analyzed the detectability of luciferin and Xist in earpunches 
and miPS clone 5 cells. The results showed that earpunches were negative for luciferase 
sequence in their genome while in miPS clone 5 cells were positive (Fig. 21). 
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We then investigated the DNA from organs and tumors, after the mice were sacrificed. The 
organs and tumor parts were pooled for each organ. The PCR results showed that Xist is 
detectable in all samples. Luciferase was not detected in spleen and liver samples (Fig. 22). 
Lung samples did show low amounts of signal for luciferase (Fig. 22). The tumors had the 
highest signal for luciferase which matches the previous observations of the miPS clone 5 
cells (Fig. 5, 6, 7 and 21). 
The necropsy of the mice could not find macroscopic evidence of migrated cells (Fig. 23). 
The organs appeared in physiological shape and color and no signs of metastasis of the 
teratoma were found (Fig. 22). The only difference appeared in the color of the teratoma 
during necropsy. WT teratoma did appear darker in color in both florid and atrophic teratoma 
(Fig. 23). GoST cell-derived teratoma did look pale compared to WT-derived teratoma, 
especially in the atrophic tumors (Fig. 20). Nevertheless there were tumors derived from WT 
cells, which were pale, and GoST cell-derived teratoma, which were darker (data not shown). 
In mouse #2 the teratoma did penetrate the abdominal wall and reached into the abdominal 
cavity, but without infiltrating or damaging the surrounding organs (Fig. 22). 
The search for migrating cells revealed a potential migration of cells into the lungs after the 
injection. The migrated cells however did not form metastasis in the lung. 
 
Fig. 21 
RT-PCR of DNA from mouse tissue and miPS clone 5 cells. Data were generated from duplicates of three 
independent experiments. The error bars correspond to the S.E.M. One star represents p<0.05, two stars 
represent p<0.01, three stars represent p<0.001. 
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Prior to the injection of the cells, the mice were marked by earpunches. The earpunch-tissue taken from each 
mouse was collected and PCR of the X-Chromosome-specific gene Xist and the transgene luciferase was 
performed. Results show that the expression of Xist is significantly lower in miPS clone 5 cells compared to ear 
punch tissue, but still detectable. The transgene luciferase is not detectable in ear punches, but detectable in high 




RT-PCR of pooled DNA from extracted organs of the necropsy. Data were generated from duplicates of three 
independent experiments. The error bars correspond to the S.E.M. One star represents p<0.05, two stars 
represent p< 0.01, three stars represent p<0.001. 
This analysis was conducted to analyze if luciferase positive cells migrated or metastasized after the injection. 
Since we could not detect the Y-chromosome-specific genes (Fig. 7), only luciferase or LacZ remained as tracers 
for these cells. We decided to use luciferase since it was sufficiently expressed in both miPS Luc/Lac and miPS 
clone 5 (Fig. 5). The X-chromosome-specific gene Xist is detectable in all organs and the difference in signal 




Macroscopic pictures of injected mice after IVIS imaging and dissection. One square = 1x1cm, one dot ≈ 2mm 
The necropsy after IVIS imaging gave more insights into the pathology of the tumors. In the overview images 
the tumors were easily visible from the external view for the tumors >15mm diameter. When skinned, most of 
the tumors did either attach to the skin or the abdominal wall, but could be separated easily and without 
alteration of the surrounding tissue. In mouse #2 the tumor did grow through the abdominal wall into the 
abdominal cavity, but did not infiltrate the surrounding tissue and organs. In other cases the GoST cell-derived 
florid teratomas stuck tightly to the skin and were not movable under the skin. Atrophic tumors were still visible 
with a small bump from the outside, but did not look as prominent as in the bigger tumors in both groups. WT 
and GoST cell-derived tumors did have a similar macroscopic morphology. They were of dark color and had a 
thin capsule that connected them to the skin or the abdominal wall. The GoST cell-derived florid teratoma did 
have a pale look compared to WT teratoma. Atrophic tumors showed some differences in the appearance 
between the two groups of injected cells. In WT cells, atrophic tumors did have a pink color similar to the florid 
tumors, while the GoST cell tumors did look pale, almost like the skin in the background. Atrophic tumors did 
only appear in the lowest cell dose of 100 injected cells in WT treated cells. In GoST cells the atrophic tumors 
appeared in all three cell dosages. Visceral organs did not show any pathologic alterations. The previously 






In the first step of this study we attempted to adapt the GoST induction from mES cells to 
miPS cell culture conditions in 2iL and further characterize GoST cells. This experiment 
proved that miPS cells survive the GoST induction culture conditions deprived of βME as 
described in mES cells1 (Fig. 9). If the GoST induction induced germ cell-like features in 
miPS cells as well, needed to be addressed in further experiments. 
 By extending the unstimulated time period of miPS-derived GoST cells to 20 days we gained 
greater insights on mRNA expression patterns during that time period. We thereby observed a 
new phenotype of cells in the GoST cell population after 16 days (Fig. 10). The second goal 
was to investigate the tumor growth potential of miPS cell-derived GoST cells in vivo. Our 
results showed that GoST cells contributed to teratoma formation, but showed reduced tumor 
growth compared to WT cells. 
The analysis of the core and naïve pluripotency markers shows that mES and miPS cells 
express the essential pluripotency markers Oct4, Sox2 and Nanog at similar levels, which 
confirms the literature11,13,25 (Fig. 1 and 2). The immunofluorescence confirmed the real-time 
RT-PCR findings with similar staining intensity in mES and miPS clone 5 cells (Fig. 4). mEF 
cells, which represent the negative control, did not express core nor naïve pluripotency 
markers, which was expected for a differentiated cell type. The only pluripotency factor 
expressed in mEF cells was Klf4. This can be explained by the function of Klf4. Klf4 
stabilizes the differentiation potential in mEF cells128 and is therefore expressed in these cells. 
However, the expression of Klf4 in mEF cells was still significantly lower than in the PS 
cells. Immunofluorescence showed heterogeneous staining of TRA98 in both mES and miPS 
clone 5 cells. This might be an effect of heterogeneous TRA98 expression in PS cells, which 
is at least partially dependent on their cell cycle (Fig. 4). 
The results of Western blot analysis on the other hand showed significant discrepancies 
between mES and miPS clone 5 cells for the expression of Nanog, Oct4 and Sox2 (Fig. 3). 
These results differ from the previous findings in mRNA quantification and 
immunofluorescence. A possible explanation might be technical and analytical errors of the 
Western blots, since the signal seems to decay towards one side of the blot and within the 
bands (Fig. 3). Nevertheless, mEF cells showed signs of expression of pluripotency markers 
in the analysis of the western blots (Fig. 3). This signal is most likely background noise of the 
western blots detected by the ImageJ software, since it is clearly visible that no bands appear 
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in mEF cells (Fig. 3). The analysis of the integrated transgenes in the miPS, mES and in the 
isolated cell clones clearly showed the presence of luciferase and LacZ in the cells (Figs. 5, 6 
and 7). The X-Gal-staining showed distinct differences between non-transgenic and 
transgenic miPS cells (Fig. 5). There are however significant differences in the detectable 
amount of transgenes of luciferase and LacZ in the mES clone 11, miPS Luc/Lac and clone 5 
cell lines (Fig. 7). It is possible that the plasmids integrated into the genome or decayed over 
time during passaging in the cell culture. This effect can be caused by unspecific multiple 
integration of the plasmid into the genome and might be insertion side dependent e.g. when 
integrated into certain promoter regions or silent integration into introns, which would affect 
the signal of the transgenes. Epigenetic modulation represents another important regulatory 
mechanism of gene expression and might be another reason for the reduced expression of 
transgenes. This effect could be evaluated by sequencing of the genome. 
But nevertheless the results showed clearly that miPS clone 5 is a pluripotent stem cell line 
that expresses reliably the introduced reporter transgenes. Therefore the reporter transgenes 
represent a reliable tool to detect the cells in vitro or in vivo. 
The analysis of the X/Y-chromosome-specific genes revealed that in the isolated cell clones 
11 and 5 the Y-Chromosome-specific genes Sry and Zfy were not detectable while the 
primers showed specificity and consistent signal in other cell lines as well as in tissue samples 
(Fig. 7). After investigating the chromosome morphology via FISH painting the source of the 
lost signal was the total loss of the Y-Chromosome (Fig. 8B). The Y-Chromosome signal in 
the FISH chromosome painting of the X-Chromosome is most likely a false-positive result 
(Fig. 8A). The Y-Chromosome consists of high density chromatin and therefore does not 
recombine with other chromsomes129. Loss or the partial deletion of the Y-Chromosome 
occurs not only as a natural event130,131 but can happen during cancer development132,133 as 
well as during culturing of stem cells and is reported in several stem cell lines used for 
scientific purposes113. The differences in signal for the X-Chromosome-specific gene Xist 
might be due to technical errors and handling of the isolated DNA like different amounts of 
pipetted DNA. The elongation of the X-Chromosome can also be taken in consideration for 
the disparity of signal. This observation might explain the observed differences in transgene 
expression, since it is possible that not only the sex chromosomes show alterations but the 
autosomal chromosomes as well. 
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Closer examination during GoST induction confirmed the observation that the chemical 
treatment protects the cells from death when deprived from 2iL medium compared to the WT 
treated cells1,73. This is mainly ascribed by the attributes of the used chemicals, in particular 
tBHQ which prevents oxidative stress through Nrf2 signaling and thereby protecting the cells 
76. The possibility that other supplements made the survival possible, like DMSO or bare BM, 
can be ruled out since the WT cells did not survive culture in BM + DMSO (Fig. 9). Thus the 
GoST induction is the key factor for the survival of the cells. Usually the ingredient β-
mercaptoethanol is essential for survival of the cells, since it raises the intracellular reduced 
form of GSH and thereby protects cells from toxic metabolites and oxidative stress and is a 
standard component of stem cell culture methods134-136. 
The mRNA expression profiles during the GoST induction period and the following 
unstimulated time period showed interesting results (Figs. 11-14). The core pluripotency 
markers decreased in both WT and GoST cells except for Klf4. Expression of core 
pluripotency markers of GoST cells were downregulated at D0 compared to WT cells. The 
upregulation of the transcriptional factor Klf4 can be caused by differentiation processes since 
Klf4, like all Krüppel-like factors, is a potent regulator of differentiation137. Since WT cells 
show downregulation and GoST cells massive upregulation of Klf4 over the whole examined 
time points, it indicates a decisive change in expression for GoST cells. Interestingly, WT 
cells showed downregulation of Klf4 but still expressed germ cell markers like GoST cells. 
Most of the naïve pluripotency markers decrease as well in WT and GoST cells. Exceptions 
are Piwil2 and Rex1 in both groups. The increase and consistent expression of Rex1 
throughout the series in both groups represents a remarkable result, since it is reported that 
Nanog, Sox2 and Oct4 bind to the promotor region of Rex115,138 and downregulation of those 
factors should result in downregulation of Rex1139. This could mean other factors or effects 
independent from these pluripotency factors mediate the maintained expression of Rex1. The 
only differentiated tissue with constant Rex1 expression, besides stem cells, are testicles140. 
Otherwise a maintained Rex1 expression would indicate an undifferentiated state of the cells 
which can be excluded, since most of the pluripotency markers are downregulated, as 
mentioned above. Piwil2 expression is linked to cell integrity and protection of DNA141 
especially in cancer142,143. This could indicate reorganization processes in the genome during 
the unstimulated time period in both WT and GoST cells. The upregulation showed the same 
trend in both cell types which hardens the suspicion that this effect results of the exclusion of 
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either the chemicals of the GoST induction or the 2i+Lif growth medium in WT cells. This 
pattern does not overlap with the Rex1 expression though. Piwil2 also was reportedly 
expressed in bovine testis, together with Ddx4, a germ cell marker144. 
As a conclusion of the analyzed pluripotency markers both WT and GoST cells have no 
longer pluripotent properties and must have differentiated. The Rex1 and Piwil2 expression 
indicates a germ cell-like state in both groups. 
The analysis of germ cell-specific markers showed decreasing expression rates of Dazl and 
Nanos2. Their peak expression lies between 4-12 days of unstimulated culturing (Fig. 13). 
Dazl is a crucial gene linked to germ cell development145 and Nanos2 is an important factor 
for maintenance of the primitive state of spermatogonial stem cells67. This indicates a germ 
cell-like state during this time period for both groups. The expression peaks do show a 
correlation with the expression patterns of Rex1, Piwil2 and Klf4, which showed their highest 
expression rates in this timeframe. This again can be related to a germ-cell like fate of the 
cells. Klf4 stands out in this regard, since the expression does not decrease after 12 days of 
culturing in unstimulated environment in GoST cells, but in WT cells. Rex1 and Piwil2 
expression increased over time and expression peaked around day 12 without stimulation. 
Interestingly the genes Tdrd1, Tex101 and Zbtb16 showed little to no expression in the PS 
cells, but increased massively throughout the 20 days. Fascinatingly Tex101, a highly specific 
marker for germ cells, is higher expressed in WT treated cells than in GoST cells. Peak 
expressions of Dazl, Ddx4 and Tdrd1 are higher in WT cells as well, but without significance. 
Plk1s1 and Zbtb16 expression rates stand out in this analysis, since the increase of expression 
in the GoST cells was significantly higher than in WT cells. This can be a result of higher 
activity of mitosis in the GoST cells during the unstimulated time period. Plk1s1 is a 
stabilizing factor for chromosome division146 and Zbtb16, also known as PLZF, codes for a 
regulatory protein that plays an important role in cancer formation in male patients147,148. 
These results confirm a tendency towards a germ cell-like fate, which is more developed in 
GoST cells as in WT treated cells. The explanation is most likely that GoST induction 
enhances the differentiation of the cells towards the germ cell line after release of inhibiting 
factors. An interesting result is the expression of germ cell markers in WT cells. 
The germ cell-like fate of both groups is also shown in the analysis of spermatogonial stem 
cell markers (Fig. 14). GoST cells showed higher and earlier expression of the spermatogonial 
stem cell markers Cd53, Csf1r, Gfra1 and Ifi203. This can be a result of differentiation 
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towards spermatogonial stem cells, which is more prevalent in GoST cells. The only 
exception is Col1a2, which shows a higher peak in WT cells early on, decreased to low levels 
and increased again with higher expression levels compared to GoST cells. Col1a2 is related 
to collagen formation and connectivity between cells149. Since the variety of tissues that 
express collagen is very high, no precise estimation can be made if WT cells differentiated 
differently than GoST cells. It is imaginable that the WT cells differentiated into connective 
tissue with germ cell features. The higher expressed collagen may be an explanation for the 
thicker cell layers in WT cells during the unstimulated time period (Fig. 10). 
After all the real-time RT-PCR results indicate a differentiation path of both groups from 
pluripotent stem cells into at least germ-like cells. These differentiation pathways seem to 
overlap, but with small differences in the end points of differentiation. Since the major 
difference between both cell types is the appearance of round cells in GoST cells, these 
differences can be explained by the influence, differentiation and proliferation of those cells 
caused by the previous GoST induction. An unexpected result was that germ cell and SSC 
marker were expressed in WT cells as well. We expected that the miPS clone 5 cells would 
not express any germ cell markers since they did not underwent the GoST induction. This 
expression pattern of the WT cells might be influenced by the added 2iL in the medium and 
the overall lower incubation time (20 days) compared to GoST cells (27 days). This would 
explain why both groups showed a lot of similar expression patterns around the same time 
points since culture conditions were the same on both groups. It is also possible that this effect 
is unique to iPS cells. Since iPS cells might have an epigenetic memory this could influence 
the differentiation pathway during the unstimulated culture period32. Therefore both groups 
show similar expression patterns of germ and SSC markers. This effect is more prevalent in 
GoST cells though. 
In ongoing work, following up on this study, WT cells were cultured for 7 days longer so that 
they were cultured in the absence of 2iL for the same duration as GoST cells. This new work 
revealed that WT cells also differentiated into round cells starting at around D23-D24. 
The images taken from the GoST series hardened the suspicion for a germ cell-like fate. Since 
the WT cells did not change their morphology other than proliferating into thicker layers of 
cells between the colonies, which goes along quiet well with the increased Col1a2 expression, 
the GoST cells did proliferate into small round cells from day 16 on which populated the 
entire culture dish until day 20. The reported morphology of spermatogonial stem cells 
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showed small round cells64,65 together with the shown TRA98 and the increasing Gfra1 
expression intensifies the suggestion that these cells have spermatogonial stem cell features 
on a molecular level. The WT cells did show TRA98 expression in the unstimulated time 
period, but not in the former colonies (Fig. 15). The TRA98 signal in WT cells can be residues 
of PS cells in the culture dish since these cells are found in the center of colonies (Fig. 16). It 
is possible that the cells rounded up due to overcrowding in the culture dish, which would 
lead to expulsion of cells to the medium. The continued TRA98 expression and the germ cell 
and SSC marker expression is a striking observation, since it would be expected that these 
cells would differentiate into neuroectodermal cells150. This should have been effecting both 
groups, but GoST cells did not grew as thick as the WT cells during the unstimulated time 
period. The GoST induction might be an explanation for the appearance of the round cells but, 
as mentioned before, the differences in incubation time in both groups has to be taken in 
account. The finding that WT and GoST cells showed the same expression patterns with 
peaks at the same time points across the investigated markers is another interesting result. 
Since GoST cells had 7 days of GoST induction prior to the unstimulated time period, the 
expression patterns were expected to be shifted in WT cells. Therefore the release of 2iL and 
the culture in unstimulated conditions is the dominating factor for the expression patterns of 
the tested markers. 
After injecting GoST cells directly at the end of the GoST induction, they still contributed to 
tumor growth. The overall tumor formation potential did not match with WT cells (Fig. 17) 
though. The decrease of pluripotency factors at D7 (Figs. 11 and 12) explains the reduced 
tumor growth, since tumor growth potential is linked to pluripotency116,126. It might be 
possible that the cells were weakened by the GoST induction and therefore could not 
proliferate in vivo like the WT cells, as displayed by the shape of the nuclei at D7 (Fig. 16). 
This is unlikely since the WT cells did show the same growth characteristics in the lowest 
injected cell dose and were injected without any treatment. The appearance of the round cells 
in GoST cells as well indicates that the GoST cells were vital and were able to proliferate in 
vitro (Fig. 10). Histological analysis showed no sign of vascularization of atrophic teratomas 
in both groups, which explains the inhibited or total lack of growth. Nourishment of the 
tumors can only be supplied via diffusion to a certain extent and tumor growth is therefore 
limited to a certain size. The reason why some tumors did develop vascular supply might lie 
in a different activation of vascular growth factor (VGF) by the cells or the surrounding tissue 
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which is crucial to tumor formation and development151. The heterogeneous cell population in 
the GoST cells with flat and high cells can be another reason for the differences in tumor 
growth. The flat cell might represent differentiated cells and the thick cell layers remaining PS 
cells (Fig. 9). This argument does not hold true for the WT cell though. Since the WT cells 
were derived from a single cell clone there can’t be differentiated subpopulations, which 
would have been visible in the immunofluorescence of pluripotency marker (Fig. 4). If a 
subpopulation would be injected, the growth curves should still show similar slopes compared 
to WT cells. It is more likely that this effect is connected to the impaired pluripotency at this 
time point. Since the hosts were highly immunocompromised animals, a host rejection can be 
ruled out as well. 
The histological analysis of the tumors did not reveal any differences between both groups, 
independent of GoST treated cells or WT cells, injected cell number and florid or atrophic 
growth. This can be ascribed to the reduced, but not eliminated pluripotency of GoST cells. 
Therefore the resulting tumors still classify as teratomas in both groups. 
The IVIS imaging and necropsy with the following screening for metastasis showed a positive 
signal in the lungs. Teratomas are usually non-malignant tumors and thus do not form 
metastasis, especially when the tumor does not have a vascular connection to the host. Since 
migrating cells would be expected to settle in terminal vessel systems, the lung is a likely 
organ for the cells. The observed differences in color of the tumors during necropsy can either 
be explained by the degree of vascularization of the tumors which, as mentioned before, could 
have been affected by the pluripotency of the injected cells. Since blood was drawn from each 
mouse after IVIS imaging it might be possible that the color of the tumors was dependent on 
the degree of exsanguination. The differences in color of the H&E staining can be ascribed to 
the predominant cell type or the cell density that each tumor consisted of. Since GoST cells 
showed different expression patterns on the mRNA level compared to WT cells, they may 
have a tendency towards forming high-density tissue in vivo, which WT cells don’t. 
6. Conclusion 
The goal of this thesis was the characterization of miPS-derived GoST cells and the 
investigation of their tumor growth potential in vivo compared to WT miPS cells. The 
injection of GoST cells on D7 may have shown reduced tumor growth but did not prevent 
teratoma formation. On the other hand GoST cells showed the promising tendency to have 
slow or no further growth in vivo at a certain size of the tumors, even at high cell doses. 
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Further analysis of the GoST cells showed loss of core and naïve pluripotency markers as well 
as the increase of certain germ- and SSC markers. This implicates that tumorigenicity should 
decrease in the process. The in vitro results also showed the possibility of a spermatogonial 
stem cell differentiation pathway of GoST cells when cultured for 20 days without stimulation 
after GoST induction. This hypothesis is substantiated by the morphology of the round cells 
and the higher expressed SSC markers. The question, if the derived round cells actually 
represent SSCs and if they can be used for regenerative medicine e.g. for reproductive 
medicine, has to be addressed in further experiments. The similar expression pattern in WT 
cells and the differences in incubation time between GoST and WT cells are another issue that 
has to be investigated in further experiments. 
7. Outlook 
Although this study added new insights to the GoST induction, the distinct molecular and 
cellular mechanisms behind the GoST induction are still not fully understood. The results of 
this study raised many questions about the effect of the GoST induction on miPS cells. Thus, 
further investigations have to be made. Especially for the purpose of using GoST cells in 
reproductive medicine for the restoration of fertility, the issue of chromosomal alterations in 
miPS clone 5 cells has to be addressed. Therefore a new cell clone has to be isolated, cultured 
and screened again for chromosomal deficiencies. A regular screening during the whole 
culturing and GoST induction processes might be necessary. Novel techniques like the 
CRISPR/Cas9 system enable the creation of transgenic cells in a more precise and safe way to 
ensure genetic stability in these cells during culture. After the new clone is isolated, another 
teratoma assay has to be performed to evaluate the tumorigenicity of these cells as well. In 
future experiments the injection time may be shifted to another time point other than D7, 
since our new results indicate a promising change in GoST cells at day 20 with the 
appearance of the round cells. Steps should be taken to find specific markers of the round 
cells to isolate and sort only round cells. It should then be possible to inject only round cells. 
To ensure that the appearance of these cells is not a one-time event, the experiment should be 
repeated to ensure that the round cells are not somehow an artifact or arbitrary reaction of the 
cells to the GoST induction. A follow-up teratoma formation study confirmed the appearance 
of round cells in miPS-derived GoST cells after approximately 16 days after release of 2iL. 
The teratoma assay was conducted with the floating fraction of the round cells and confirmed 
that the round cells do not contribute to teratoma formation, but survive in vivo. Nevertheless, 
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further investigation of this new cell type is necessary. To explore these round cells more 
closely they should be directly compared to SSC’s taken from mice testes. Real-time RT-PCR 
of mRNA and immunofluorescence with TRA98 and Gfra1 might be a valuable tool for 
identification of the round cells. This would also improve future data since this study lacked a 
positive control for germ cell and SSC markers. A mass spectrum analysis compared to actual 
spermatogonial stem cells might also be beneficial for a broader comparison between actual 
germ cells and the GoST-derived round cells. Murine SSC’s can be obtained e.g. by isolation 
from neonatal or premature mice. Another interesting experiment could be the analysis of the 
DNA methylation grade of GoST cells during GoST induction and the unstimulated time 
period, since the degree of methylation is an important factor for germ cell development and 
has yet not been addressed in this study.  
The final step would then be the injection of the round cells into a mouse testis. If the round 
cells represent SSC they should be capable of differentiating into fertile sperm when brought 
to their putative physiological location. For this experiment a busulfan treatment of mice 
could be used to sterilize the male mice before injection. Another possibility could be the 
usage of genetically sterile mice, which lack germ cells in the testis. A prerequisite for such 
experiments would be an intact blood-testis barrier to prevent host rejection. Transplantation 
of germ cells into germ cell-depleted testis has been shown to be very effective152 and would 
fit the purpose of treating chemotherapy induced infertility in men as well. Since this study 
only used murine stem cells so far and the ultimate goal for GoST cell applications lies in 
human reproduction medicine, the GoST induction must be adapted to human iPS cells as 
well. Recent discoveries that lead back human ES cells from their primed to a naïve 
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SCORE SHEET and MONITORING- Paragraph 56.2.1 
One score sheet represents one cage with the maximum of 5 animals. In case of obtaining 
the score result ≥6 in one of the animals, this particular animal will be entitled to its 
separate, individual score sheet. 
I. Routine Monitoring will consist of: 
a) Checking presence of food and water, the bedding state, animals wellbeing – 
performed daily in the first 3 days after injection and then 3 times per 
week (Form A filled out) 
b) Visual Inspection (performed 3 times a week – SCORE SHEET filled out):  
 Examination from a distance (performed 3 times a week – 
SCORE SHEET filled out) 
 Observation after stimulus (performed 3 times a week – SCORE 
SHEET filled out) 
If any of the animals looks/behaves suspicious (all animals at least once a week 
or more if indicated by the score obtained) 
 Close observation of an individual animal after restrain (at least 
once a week up to daily depending on the scoring result - 
















          
 
Descriptions and scoring: 
 
 
1) Gen. Appear., Mobility - General Appearance (includes skin, orifices, posture and 
locomotion) – please see Appendix I at the end of this policy for graphics to be used 
for the BCS (Body Conditioning Scale). 
Description Score 
No changes, normal behaviour and locomotion, fur clean and 
well groomed, pink mucus membranes, bright, alert, responsive 
(BCS = 3) 
0 
Fur not well groomed or excessive grooming, less active, normal 
posture and locomotion, normal respiratory rate 60-220/min 
2 
Skin or hair coat in poor condition (scruffy, dirty, fur loss), 
excessive licking and scratching of the affected site, less active or 
hyperactive, disoriented, aggressive, decreased signs of 
grooming, pale mucus membranes (BCS = 2), normal posture 
8 
Skin or coat in poor condition (swellings, atypical wrinkles, 
inflammatory reaction), self-damage, dehydration (decreased skin 
elasticity), emaciated, inactive, restriction of movement/motor 
activity, abnormal posture (curvature of the back, stretching of 
head and neck, up-drown abdominal wall, stretching of the body) 
(BCS = 1) 
12 
Moribund or severe cachexia, immobile 12 
 
2) Tumor size/Necr. – Tumor size, degree of necrosis, tumor characteristics 
Description Score 
No tumor, tumor very small (≤ 5 mm length at its longest 
diameter), not limiting mobility, not limiting ability to eat or 
breathe 
0 
Recurrent scratching/biting of tumor, acute burst releasing fluid, 
tumor is pronounced, ≥ 5 mm length at its longest diameter 4 
Locomotion impeded, chronically wet/weeping scab/crust or 
solid yellow matter exposed, ulceration, tumor size ≥ 15 mm 
length at its longest diameter 
12 
Bleeding, raw tissue exposed, white basal layer exposed, necrosis 12 
 




Routine monitoring 0-5 
Close observation – up to daily monitoring. May put food and/or 
a water source on cage bottom and/or give SC or IP saline or 
Lactated Ringer’s Solution. 
6-11 




Body Condition Scoring (BCS) 
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